Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Autoimmune Disorders

  Free Subscription

Articles published in J Neuroimmunol

Retrieve available abstracts of 487 articles:
HTML format

Single Articles

    October 2021
  1. ZELADA-RIOS L, Pacheco-Barrios K, Galecio-Castillo M, Yamunaque-Chunga C, et al
    Acute disseminated encephalomyelitis and COVID-19: A systematic synthesis of worldwide cases.
    J Neuroimmunol. 2021;359:577674.
    PubMed     Abstract available

    September 2021
  2. OO WM, Giri P, de Souza A
    AstraZeneca COVID-19 vaccine and Guillain- Barre Syndrome in Tasmania: A causal link?
    J Neuroimmunol. 2021;360:577719.
    PubMed     Abstract available

    Commentary: The spectrum of neurological manifestations related to COVID-19 and vaccinations.
    J Neuroimmunol. 2021;358:577660.

  4. GHOSH R, Dubey S, Mandal A, Ray BK, et al
    Complex movement disorders in SARS-CoV-2 infection induced acute disseminated encephalomyelitis.
    J Neuroimmunol. 2021;358:577655.
    PubMed     Abstract available

  5. PAGENKOPF C, Sudmeyer M
    A case of longitudinally extensive transverse myelitis following vaccination against Covid-19.
    J Neuroimmunol. 2021;358:577606.
    PubMed     Abstract available

  6. SRIWASTAVA S, Kataria S, Srivastava S, Kazemlou S, et al
    Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis.
    J Neuroimmunol. 2021;360:577721.
    PubMed     Abstract available

  7. PHILLIPS O, Tubre T, Lorenco H, Batish SD, et al
    Limbic encephalitis in a child with ovarian teratoma and influenza B. Case report and critical review of the history of autoimmune anti-N-methyl-d-aspartate receptor encephalitis.
    J Neuroimmunol. 2021;360:577716.
    PubMed     Abstract available

    August 2021
  8. HAYASHI F, Isobe N, Cossu D, Yokoyama K, et al
    Elevated mycobacterium avium subsp. paratuberculosis (MAP) antibody titer in Japanese multiple sclerosis.
    J Neuroimmunol. 2021;360:577701.
    PubMed     Abstract available

  9. FARSHBAFNADI M, Agah E, Rezaei N
    The second brain: The connection between gut microbiota composition and multiple sclerosis.
    J Neuroimmunol. 2021;360:577700.
    PubMed     Abstract available

  10. RIBES GARCIA S, Casanova Estruch B, Gomez Pajares F, Juan Blanco MA, et al
    Prognostic utility of the IgM oligoclonal bands against myelin lipids in multiple sclerosis.
    J Neuroimmunol. 2021;359:577698.
    PubMed     Abstract available

  11. HABEK M, Jakob Brecl G, Basic Kes V, Rogic D, et al
    Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study.
    J Neuroimmunol. 2021;359:577696.
    PubMed     Abstract available

  12. QIAO X, Wang H, Lu L, Chen J, et al
    Hippocampal microglia CD40 mediates NPSLE cognitive dysfunction in mice.
    J Neuroimmunol. 2021;357:577620.
    PubMed     Abstract available

  13. CHAKRABORTY AP, Pandit A, Ray BK, Mukherjee A, et al
    Capgras syndrome and confabulation unfurling anti NMDAR encephalitis with classical papillary thyroid carcinoma: First reported case.
    J Neuroimmunol. 2021;357:577611.
    PubMed     Abstract available

  14. EQUIZA J, Rodriguez-Antiguedad J, Campo-Caballero D, Iruzubieta P, et al
    Autoimmune GFAP astrocytopathy presenting with remarkable CNS hyperexcitability and oculogyric crises.
    J Neuroimmunol. 2021;359:577695.
    PubMed     Abstract available

  15. COSSU D, Yokoyama K, Sato S, Noda S, et al
    PARKIN modifies peripheral immune response and increases neuroinflammation in active experimental autoimmune encephalomyelitis (EAE).
    J Neuroimmunol. 2021;359:577694.
    PubMed     Abstract available

  16. MIN YG, Ju W, Ha YE, Ban JJ, et al
    Sensory Guillain-Barre syndrome following the ChAdOx1 nCov-19 vaccine: Report of two cases and review of literature.
    J Neuroimmunol. 2021;359:577691.
    PubMed     Abstract available

  17. HAHAM N, Vaknin-Dembinsky A
    COVID-19 in Cladribine-treated patient with multiple sclerosis.
    J Neuroimmunol. 2021;359:577690.
    PubMed     Abstract available

    July 2021
  18. KRAUS EE, Kakuk-Atkins L, Farinas MF, Jeffers M, et al
    Regulation of autoreactive CD4 T cells by FoxO1 signaling in CNS autoimmunity.
    J Neuroimmunol. 2021;359:577675.
    PubMed     Abstract available

  19. LOVETT-RACKE AE, Yang Y, Liu Y, Gormley M, et al
    B cell depletion changes the immune cell profile in multiple sclerosis patients: One-year report.
    J Neuroimmunol. 2021;359:577676.
    PubMed     Abstract available

  20. LAI QL, Cai MT, Zheng Y, Zhang TY, et al
    Seasonal variation in autoimmune encephalitis: A multi-center retrospective study.
    J Neuroimmunol. 2021;359:577673.
    PubMed     Abstract available

  21. YAO Y, Li X, Lin J, Zhang X, et al
    Thymoma-associated autoimmune encephalitis with positive Titin antibodies: A case report.
    J Neuroimmunol. 2021;358:577670.
    PubMed     Abstract available

  22. GUO L, Ren H, Fan S, Guan H, et al
    Autoantibody against the Rab6A/Rab6B in primary autoimmune cerebellar ataxia associated with Sjogren's syndrome: A case report.
    J Neuroimmunol. 2021;359:577667.
    PubMed     Abstract available

  23. WANG J, Yan C, Zhao Z, Chen H, et al
    Sexual dysfunction in patients with myasthenia gravis.
    J Neuroimmunol. 2021;358:577669.
    PubMed     Abstract available

  24. CAPARO-ZAMALLOA C, Alvarez-Toledo K, Yamunaque-Chunga C, Castro-Suarez S, et al
    Autoimmune neurology: Co-occurrence of anti-NMDAR encephalitis and anti-MOG associated disease, report of a case.
    J Neuroimmunol. 2021;358:577663.
    PubMed     Abstract available

  25. LOCKHART A, Boers P
    Paraneoplastic neurologic syndromes with multiple neural autoantibodies: A report of two cases.
    J Neuroimmunol. 2021;358:577665.
    PubMed     Abstract available

  26. LI R, Wang J, Li C, Liu X, et al
    Rescue immunoadsorption treatment for neuromyelitis optica spectrum disorder attacks unresponsive to intravenous methylprednisolone.
    J Neuroimmunol. 2021;356:577604.
    PubMed     Abstract available

  27. DINOTO A, Cheli M, Bratina A, Sartori A, et al
    Bortezomib in anti-N-Methyl-d-Aspartate-Receptor (NMDA-R) encephalitis: A systematic review.
    J Neuroimmunol. 2021;356:577586.
    PubMed     Abstract available

  28. NARESH K, Miraclin TA, Prabhakar AT, Mathew V, et al
    Epstein-Barr virus infection in a woman with aquaporin-4 seropositive neuromyelitis optica.
    J Neuroimmunol. 2021;356:577581.
    PubMed     Abstract available

  29. WONG CK, Hor JY, Loo YP, Heng HS, et al
    High incidence of NMDAR encephalitis among Austronesians: A population-based study in Sabah, Malaysia.
    J Neuroimmunol. 2021;356:577584.
    PubMed     Abstract available

  30. HONGO Y, Kaida K, Komuta Y, Takazaki H, et al
    Cholesterol-added antigens can enhance antiglycolipid antibody activity: Application to antibody testing.
    J Neuroimmunol. 2021;356:577580.
    PubMed     Abstract available

  31. NISHRI Y, Fainstein N, Goldfarb S, Hampton D, et al
    Modeling compartmentalized chronic immune-mediated demyelinating CNS disease in the Biozzi ABH mouse.
    J Neuroimmunol. 2021;356:577582.
    PubMed     Abstract available

  32. MIMPEN M, Damoiseaux J, van Doorn W, Rolf L, et al
    Proportions of circulating transitional B cells associate with MRI activity in interferon beta-treated multiple sclerosis patients.
    J Neuroimmunol. 2021;358:577664.
    PubMed     Abstract available

  33. CORTES-VICENTE E, Alvarez-Velasco R, Illa I, Gallardo E, et al
    Comment to "Autoantibodies to cortactin and agrin in sera of patients with myasthenia gravis".
    J Neuroimmunol. 2021;358:577659.

  34. IVANOVA M, Voronkova A, Sukhorukov V, Zakharova M, et al
    Different neuroinflammatory gene expression profiles in highly active and benign multiple sclerosis.
    J Neuroimmunol. 2021;358:577650.
    PubMed     Abstract available

  35. KHANMOHAMMADI S, Malekpour M, Jabbari P, Rezaei N, et al
    Genetic basis of Guillain-Barre syndrome.
    J Neuroimmunol. 2021;358:577651.
    PubMed     Abstract available

    June 2021
  36. MOSTAFA GA, Meguid NA, Shehab AAS, Elsaeid A, et al
    Plasma levels of nerve growth factor in Egyptian autistic children: Relation to hyperserotonemia and autoimmunity.
    J Neuroimmunol. 2021;358:577638.
    PubMed     Abstract available

  37. MIRZAEI R, Zamani F, Hajibaba M, Rasouli-Saravani A, et al
    The pathogenic, therapeutic and diagnostic role of exosomal microrna in the autoimmune diseases.
    J Neuroimmunol. 2021;358:577640.
    PubMed     Abstract available

  38. JAKHMOLA S, Upadhyay A, Jain K, Mishra A, et al
    Herpesviruses and the hidden links to Multiple Sclerosis neuropathology.
    J Neuroimmunol. 2021;358:577636.
    PubMed     Abstract available

  39. UZAWA A, Akamine H, Kojima Y, Ozawa Y, et al
    High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis.
    J Neuroimmunol. 2021;358:577634.
    PubMed     Abstract available

    Steroid-responsive, transverse myelitis is a known complication of COVID-19.
    J Neuroimmunol. 2021;355:577566.

  41. LEE JK, Kwon S, Han JH, Yoon SE, et al
    Increased proportion of CD20+ T cells after rituximab treatment in patient with neuromyelitis optica later diagnosed with lung B-cell lymphoma: A case report.
    J Neuroimmunol. 2021;355:577564.
    PubMed     Abstract available

  42. GOVIL-DALELA T, Datta I, Williams M
    Refractory NMDA-receptor encephalitis in a teenager: A novel use of Bortezomib.
    J Neuroimmunol. 2021;355:577565.
    PubMed     Abstract available

  43. SON H, Lee WJ, Moon J, Yoon S, et al
    Isolated CNS involvement in eosinophilic granulomatosis with polyangiitis treated with mepolizumab: A case report.
    J Neuroimmunol. 2021;355:577551.
    PubMed     Abstract available

  44. REYES S, Cunningham AL, Kalincik T, Havrdova EK, et al
    Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement.
    J Neuroimmunol. 2021;357:577627.
    PubMed     Abstract available

  45. FINSTERER J, Ghosh R
    Dimensions of SARS-CoV-2 associated Guillain-Barre syndrome.
    J Neuroimmunol. 2021;357:577626.

  46. NIINO M, Fukazawa T, Miyazaki Y, Ura S, et al
    Seasonal fluctuations in serum levels of vitamin D in Japanese patients with multiple sclerosis.
    J Neuroimmunol. 2021;357:577624.
    PubMed     Abstract available

    May 2021
  47. GRISANTI SG, Franciotta D, Garnero M, Zuppa A, et al
    A case series of parainfectious Guillain-Barre syndrome linked to influenza A (H1N1) virus infection.
    J Neuroimmunol. 2021;357:577605.
    PubMed     Abstract available

  48. MANOUCHEHRI N, Guisso DR, Hussain RZ, Minassian BA, et al
    The antioxidant MnTBAP does not effectively downregulate CD4 expression in T cells in vivo.
    J Neuroimmunol. 2021;354:577544.
    PubMed     Abstract available

  49. WANG T, Wang B, Zeng Z, Li H, et al
    Efficacy and safety of bortezomib in rituximab-resistant anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis as well as the clinical characteristics: An observational study.
    J Neuroimmunol. 2021;354:577527.
    PubMed     Abstract available

  50. FINSTERER J, Scorza FA, Scorza CA, Fiorini AC, et al
    Diagnosing SARS-CoV-2 associated Guillain-Barre syndrome requires cerebro-spinal-fluid studies.
    J Neuroimmunol. 2021;357:577609.

  51. SVIRIDOVA A, Rogovskii V, Kudrin V, Pashenkov M, et al
    The role of 5-HT2B-receptors in fluoxetine-mediated modulation of Th17- and Th1-cells in multiple sclerosis.
    J Neuroimmunol. 2021;356:577608.
    PubMed     Abstract available

  52. ROTOLO RA, Demuro J, Drummond G, Little C, et al
    Prophylactic exposure to oral riluzole reduces the clinical severity and immune-related biomarkers of experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2021;356:577603.
    PubMed     Abstract available

  53. SOLTANMORADI S, Tavakolpour V, Moghadasi AN, Kouhkan F, et al
    Expression analysis of NF-kappaB-associated long noncoding RNAs in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients.
    J Neuroimmunol. 2021;356:577602.
    PubMed     Abstract available

  54. KELLY H, Sokola B, Abboud H
    Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients.
    J Neuroimmunol. 2021;356:577599.
    PubMed     Abstract available

  55. ZULIANI L, Marangoni S, De Gaspari P, Rosellini I, et al
    Epidemiology of neuronal surface antibody-mediated autoimmune encephalitis and antibody-based diagnostics.
    J Neuroimmunol. 2021 May 1:577598. doi: 10.1016/j.jneuroim.2021.577598.
    PubMed     Abstract available

    April 2021
  56. YOKOTE H
    Author's response in reply to "Question about data: Importance of serum amyloid A level in patients with multiple sclerosis".
    J Neuroimmunol. 2021;356:577589.

  57. DOPPLER K, Hemprich A, Haarmann A, Brecht I, et al
    Autoantibodies to cortactin and agrin in sera of patients with myasthenia gravis.
    J Neuroimmunol. 2021;356:577588.
    PubMed     Abstract available

  58. GARCIA-MANTEIGA JM, Clarelli F, Bonfiglio S, Mascia E, et al
    Identification of differential DNA methylation associated with multiple sclerosis: A family-based study.
    J Neuroimmunol. 2021;356:577600.
    PubMed     Abstract available

  59. MASI G, Spagni G, Campetella L, Monte G, et al
    Assessing the role of a tissue-based assay in the diagnostic algorithm of autoimmune encephalitis.
    J Neuroimmunol. 2021;356:577601.
    PubMed     Abstract available

  60. PAPRI N, Hayat S, Mohammed A, Afsar MNA, et al
    Guillain-Barre syndrome associated with SARS-CoV-2 infection: A case report with long term follow up.
    J Neuroimmunol. 2021;356:577590.
    PubMed     Abstract available

  61. HOU H, Sun Y, Miao J, Gao M, et al
    Ponesimod modulates the Th1/Th17/Treg cell balance and ameliorates disease in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2021;356:577583.
    PubMed     Abstract available

  62. SHEIKH AB, Chourasia PK, Javed N, Chourasia MK, et al
    Association of Guillain-Barre syndrome with COVID-19 infection: An updated systematic review.
    J Neuroimmunol. 2021;355:577577.
    PubMed     Abstract available

  63. MORENO-ESCOBAR MC, Kataria S, Khan E, Subedi R, et al
    Acute transverse myelitis with Dysautonomia following SARS-CoV-2 infection: A case report and review of literature.
    J Neuroimmunol. 2021;353:577523.
    PubMed     Abstract available

  64. JUMAH M, Rahman F, Figgie M, Prasad A, et al
    COVID-19, HHV6 and MOG antibody: A perfect storm.
    J Neuroimmunol. 2021;353:577521.
    PubMed     Abstract available

  65. WANG J, Qiu Z, Li D, Dong H, et al
    Anti-contactin-associated protein-like 2 antibody-associated cerebellar ataxia: A case report and literature review.
    J Neuroimmunol. 2021;353:577515.
    PubMed     Abstract available

  66. ZHANG H, Yang Y, Luo X
    Anti-MOG antibodies associated demyelination following encephalomeningitis: Case report.
    J Neuroimmunol. 2021;353:577519.
    PubMed     Abstract available

  67. LI C, Wang J, Sun X, Li R, et al
    The current situation of diagnosis and treatment of neuromyelitis optica spectrum disorder: Experience with 461 cases from a single centre in South China.
    J Neuroimmunol. 2021;353:577506.
    PubMed     Abstract available

  68. DIEM L, Hoepner R, Bagnoud M, Salmen A, et al
    Natalizumab induced blood eosinophilia: A retrospective pharmacovigilance cohort study and review of the literature.
    J Neuroimmunol. 2021;353:577505.
    PubMed     Abstract available

  69. FANG F, Wang Y, Xu W
    Anti-N-methyl-d-aspartate receptor encephalitis associated with intracranial cryptococcal infection: A case report and 2-year follow-up.
    J Neuroimmunol. 2021;353:577502.
    PubMed     Abstract available

  70. DU Q, Shi Z, Chen H, Zhang Y, et al
    Comparison of clinical characteristics and prognoses in patients with different AQP4-Ab and MOG-Ab serostatus with neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2021;353:577494.
    PubMed     Abstract available

  71. PRADO MB JR, Narito KM, Adiao KJB
    Anti-GM1 IgM antibody positive axonal variant of Guillain-Barre-syndrome in a pediatric patient with dengue fever.
    J Neuroimmunol. 2021;355:577572.
    PubMed     Abstract available

  72. FAN Z, Zheng D, Wen X, Shen F, et al
    CYP3A5*3 polymorphism and age affect tacrolimus blood trough concentration in myasthenia gravis patients.
    J Neuroimmunol. 2021;355:577571.
    PubMed     Abstract available

  73. DINIZ SN, da Silva CF, de Almeida IT, da Silva Costa FE, et al
    INFbeta treatment affects global DNA methylation in monocytes of patients with multiple sclerosis.
    J Neuroimmunol. 2021;355:577563.
    PubMed     Abstract available

    March 2021
  74. GUEDES BF, Ribeiro AF, Pinto LF, Vidal JE, et al
    Potential autoimmune encephalitis following yellow fever vaccination: A report of three cases.
    J Neuroimmunol. 2021;355:577548.
    PubMed     Abstract available

  75. LAZAREVIC M, Djedovic N, Stanisavljevic S, Dimitrijevic M, et al
    Complete Freund's adjuvant-free experimental autoimmune encephalomyelitis in Dark Agouti rats is a valuable tool for multiple sclerosis studies.
    J Neuroimmunol. 2021;354:577547.
    PubMed     Abstract available

  76. DINOTO A, Bosco A, Sartori A, Bratina A, et al
    Hiccups, severe vomiting and longitudinally extensive transverse myelitis in a patient with prostatic adenocarcinoma and Aquaporin-4 antibodies.
    J Neuroimmunol. 2021;352:577488.
    PubMed     Abstract available

  77. LI X, Hou C, Wu WL, Liang H, et al
    Pediatric anti-N-methyl-d-aspartate receptor encephalitis in southern China: Analysis of 111 cases.
    J Neuroimmunol. 2021;352:577479.
    PubMed     Abstract available

  78. DAY GS, Gordon BA, Bucelli RC, Perrin RJ, et al
    Leveraging molecular biomarkers to make the common diagnosis in the uncommon patient.
    J Neuroimmunol. 2021;352:577474.
    PubMed     Abstract available

  79. COSSU D, Yokoyama K, Sakanishi T, Kuwahara-Arai K, et al
    A mucosal immune response induced by oral administration of heat-killed Mycobacterium avium subsp. paratuberculosis exacerbates EAE.
    J Neuroimmunol. 2021;352:577477.
    PubMed     Abstract available

  80. CHAUDHARY P, Marracci GH, Calkins E, Pocius E, et al
    Thyroid hormone and thyromimetics inhibit myelin and axonal degeneration and oligodendrocyte loss in EAE.
    J Neuroimmunol. 2021;352:577468.
    PubMed     Abstract available

  81. GIARRAPUTO J, Giamberardino S, Arvai S, Maichle S, et al
    Profiling serum neurofilament light chain and glial fibrillary acidic protein in primary progressive multiple sclerosis.
    J Neuroimmunol. 2021;354:577541.
    PubMed     Abstract available

    February 2021
  82. XIANG W, Xie C, Guan Y
    The identification, development and therapeutic potential of IL-10-producing regulatory B cells in multiple sclerosis.
    J Neuroimmunol. 2021;354:577520.
    PubMed     Abstract available

  83. LI H, Huang Z, Jia D, Xue H, et al
    Low-dose rituximab treatment for new-onset generalized myasthenia gravis.
    J Neuroimmunol. 2021;354:577528.
    PubMed     Abstract available

  84. LUCCHINI M, Giuffre GM, Nociti V, Bianco A, et al
    Defining the disease course of TNFalpha blockers-associated Multiple Sclerosis.
    J Neuroimmunol. 2021;353:577525.
    PubMed     Abstract available

  85. AKAISHI T, Misu T, Takahashi T, Takai Y, et al
    Progression pattern of neurological disability with respect to clinical attacks in anti-MOG antibody-associated disorders.
    J Neuroimmunol. 2021;351:577467.
    PubMed     Abstract available

  86. CHOUDHARY A, Bhargava A, Khichar S, Pradhan S, et al
    Etiological spectrum, clinico-radiological profile and treatment outcomes of longitudinally extensive transverse myelitis - A prospective study from Northwest India.
    J Neuroimmunol. 2021;351:577456.
    PubMed     Abstract available

  87. THIRUNAVUKKARASU B, Gupta K, Nada R, Rathi M, et al
    Neuropathological spectrum in systemic lupus erythematosus: A single institute autopsy experience.
    J Neuroimmunol. 2021;353:577518.
    PubMed     Abstract available

  88. UCHIDA N, Mori K, Fujita-Nakata M, Nakanishi M, et al
    Systemic cellular immunity and neuroinflammation during acute flare-up in multiple sclerosis and neuromyelitis optica spectrum disorder patients.
    J Neuroimmunol. 2021;353:577500.
    PubMed     Abstract available

  89. LI Q, Liu Y, Zeng Y
    Questions about data: Importance of serum amyloid A level in patients with multiple sclerosis.
    J Neuroimmunol. 2021;353:577516.

    January 2021
  90. YUE YX, Gao X, Tang TP, Xie Y, et al
    Complement C3 polymorphism is associated with the susceptibility of myasthenia gravis in Chinese adult patients.
    J Neuroimmunol. 2021;353:577487.
    PubMed     Abstract available

  91. BEER R, Lehn A, Blum S
    A case of Anti-LGi-1 antibody positive autoimmune epilepsy following deep brain stimulator implantation for essential tremor.
    J Neuroimmunol. 2021;353:577503.
    PubMed     Abstract available

  92. NING P, Yang B, Yang X, Huang H, et al
    Lymphocyte-based ratios for predicting respiratory failure in Guillain-Barre syndrome.
    J Neuroimmunol. 2021;353:577504.
    PubMed     Abstract available

  93. KHADEMI B, Khorrami M, Ayromlou H, Rikhtegar R, et al
    An interdependence between GAPVD1 gene polymorphism, expression level and response to interferon beta in patients with multiple sclerosis.
    J Neuroimmunol. 2021;353:577507.
    PubMed     Abstract available

  94. BROADLEY J, Wesselingh R, Seneviratne U, Kyndt C, et al
    Prognostic value of acute cerebrospinal fluid abnormalities in antibody-positive autoimmune encephalitis.
    J Neuroimmunol. 2021;353:577508.
    PubMed     Abstract available

  95. MIMPEN M, Rolf L, Muris AH, Gerlach O, et al
    NK/T cell ratios associate with interleukin-2 receptor alpha chain expression and shedding in multiple sclerosis.
    J Neuroimmunol. 2021;353:577499.
    PubMed     Abstract available

  96. ONMAZ DE, Isik SMT, Abusoglu S, Ekmekci AH, et al
    Serum ADMA levels were positively correlated with EDSS scores in patients with multiple sclerosis.
    J Neuroimmunol. 2021;353:577497.
    PubMed     Abstract available

  97. NIU Y, Li Y
    The serum alpha-synuclein levels in patients with multiple sclerosis need more evidence.
    J Neuroimmunol. 2021;352:577465.

  98. MORIGUCHI K, Miyamoto K, Fukumoto Y, Kusunoki S, et al
    Change in light-dark cycle affects experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2021;353:577495.
    PubMed     Abstract available

  99. CHU Y, Jing Y, Zhao X, Wang M, et al
    Modulation of the HMGB1/TLR4/NF-kappaB signaling pathway in the CNS by matrine in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2021;352:577480.
    PubMed     Abstract available

  100. ZILIOTTO N, Lamberti N, Manfredini F, Straudi S, et al
    Baseline and overtime variations of soluble adhesion molecule plasma concentrations are associated with mobility recovery after rehabilitation in multiple sclerosis patients.
    J Neuroimmunol. 2021;352:577473.
    PubMed     Abstract available

    December 2020
  101. KOHLE F, Sprenger A, Klein I, Fink GR, et al
    Nerve conductions studies in experimental models of autoimmune neuritis: A meta-analysis and guideline.
    J Neuroimmunol. 2020;352:577470.
    PubMed     Abstract available

  102. STASCHEIT F, Li L, Mai K, Baum K, et al
    Delayed onset hypophysitis after therapy with daclizumab for multiple sclerosis - A report of two cases.
    J Neuroimmunol. 2020;351:577469.
    PubMed     Abstract available

  103. YOKOTE H, Toru S, Nishida Y, Hattori T, et al
    Serum amyloid A level correlates with T2 lesion volume and cortical volume in patients with multiple sclerosis.
    J Neuroimmunol. 2020;351:577466.
    PubMed     Abstract available

  104. AKAISHI T, Fujimori J, Takahashi T, Misu T, et al
    Seasonal variation of onset in patients with anti-aquaporin-4 antibodies and anti-myelin oligodendrocyte glycoprotein antibody.
    J Neuroimmunol. 2020;349:577431.
    PubMed     Abstract available

  105. UZAWA A, Ozawa Y, Yasuda M, Kuwabara S, et al
    Severe worsening of myasthenic symptoms after the eculizumab discontinuation.
    J Neuroimmunol. 2020;349:577424.
    PubMed     Abstract available

  106. GARCIA-FERNANDEZ FJ, Garcia-Fernandez AE, Nava E, Del Pozo JSG, et al
    A bibliometric evaluation of the top 100 cited natalizumab articles.
    J Neuroimmunol. 2020;349:577379.
    PubMed     Abstract available

  107. HUSSEIN O, Abd Elazim A, Torbey MT
    Covid-19 systemic infection exacerbates pre-existing acute disseminated encephalomyelitis (ADEM).
    J Neuroimmunol. 2020;349:577405.
    PubMed     Abstract available

  108. ZHENG Y, Luo J, Jin H, Gao F, et al
    Cerebrospinal fluid CD20 positive B-cell expansion in a case of anti-NMDAR encephalitis.
    J Neuroimmunol. 2020;349:577365.
    PubMed     Abstract available

    November 2020
  109. MOUTRAN-BARROSO H, Kreinter-Rosembaun H, Beltran S MA, Bayona H, et al
    The multiple faces of encephalitis: Antibody profile in a case series of autoimmune encephalitis in Bogota, Colombia.
    J Neuroimmunol. 2020;350:577451.
    PubMed     Abstract available

  110. MA X, Kermode AG, Hu X, Qiu W, et al
    NMOSD acute attack: Understanding, treatment and innovative treatment prospect.
    J Neuroimmunol. 2020;348:577387.
    PubMed     Abstract available

  111. GHOSH R, Dubey S, Ray BK, Purkait S, et al
    Isolated opsoclonus heralding neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2020;348:577394.
    PubMed     Abstract available

  112. XING X, Li J, Chen S, Zheng L, et al
    Anti-CASPR2 antibody associated encephalitis with anosmia and demyelinating pseudotumor: A case report.
    J Neuroimmunol. 2020;348:577393.
    PubMed     Abstract available

  113. KWON YN, Kim B, Ahn S, Seo J, et al
    Serum level of IL-1beta in patients with inflammatory demyelinating disease: Marked upregulation in the early acute phase of MOG antibody associated disease (MOGAD).
    J Neuroimmunol. 2020;348:577361.
    PubMed     Abstract available

  114. GUO J, Han B, Wang J, Zhang L, et al
    The differential expression and potential roles of circular RNAs in children with anti-NMDA receptor encephalitis.
    J Neuroimmunol. 2020;348:577381.
    PubMed     Abstract available

  115. BILGE N, Simsek F, Yevgi R, Ceylan M, et al
    Low serum Alpha-SYNUCLEIN and oligomer Alpha-SYNUCLEIN levels in multiple sclerosis patients.
    J Neuroimmunol. 2020;350:577432.
    PubMed     Abstract available

  116. MONTEIRO A, Rosado P, Rosado L, Fonseca AM, et al
    Alterations in peripheral blood monocyte and dendritic cell subset homeostasis in relapsing-remitting multiple sclerosis patients.
    J Neuroimmunol. 2020;350:577433.
    PubMed     Abstract available

  117. GONCALVES MVM, Brandao WN, Longo C, Peron JPS, et al
    Correlation between IL-31 and sCD40L plasma levels in Fingolimod-treated patients with Relapsing-Remitting Multiple Sclerosis (RRMS).
    J Neuroimmunol. 2020;350:577435.
    PubMed     Abstract available

    October 2020
  118. SUN H, Wang J, Guo L, Wang Y, et al
    The combined treatment of NAD(+) and atorvastatin ameliorates the development of experimental autoimmune encephalomyelitis in C57BL/6 mice.
    J Neuroimmunol. 2020;350:577429.
    PubMed     Abstract available

  119. MARTINEZ-LARROSA J, Matute-Blanch C, Montalban X, Comabella M, et al
    Modelling multiple sclerosis using induced pluripotent stem cells.
    J Neuroimmunol. 2020;349:577425.
    PubMed     Abstract available

  120. JEBALI A, Noroozi Karimabad M, Ahmadi Z, Khorramdel H, et al
    Attenuation of inflammatory response in the EAE model by PEGlated nanoliposome of pistachio oils.
    J Neuroimmunol. 2020;347:577352.
    PubMed     Abstract available

  121. QIU Y, Zhou Q, Du Q, Chen H, et al
    Seasonal variation in relapse of neuromyelitis optica spectrum disorders: A retrospective study in China.
    J Neuroimmunol. 2020;347:577351.

  122. DUBEY S, Ghosh R, Dubey MJ, Sengupta S, et al
    Bilateral thalamic changes in anti-NMDAR encephalitis presenting with hemichorea and dystonia and acute transient psychotic disorder.
    J Neuroimmunol. 2020;347:577329.
    PubMed     Abstract available

  123. LI HX, Zuo L, Peng XX, Zong Q, et al
    Immunoglobulin G4-related hypertrophic pachymeningitis with spinal cord compression: A case report.
    J Neuroimmunol. 2020;347:577325.
    PubMed     Abstract available

    September 2020
  124. MATTEO G, Massimiliano T, Giorgia C, Silvia S, et al
    AQP4 autoantibodies in patients with idiopathic normal pressure hydrocephalus.
    J Neuroimmunol. 2020;349:577407.
    PubMed     Abstract available

  125. NEKRASOVA I, Shirshev S
    Estriol in regulation of cell-mediated immune reactions in multiple sclerosis.
    J Neuroimmunol. 2020;349:577421.
    PubMed     Abstract available

  126. HAWKE S, Zinger A, Juillard PG, Holdaway K, et al
    Selective modulation of trans-endothelial migration of lymphocyte subsets in multiple sclerosis patients under fingolimod treatment.
    J Neuroimmunol. 2020;349:577392.
    PubMed     Abstract available

  127. YAN C, Zhao R, Song J, Feng X, et al
    Comparison of anti-acetylcholine receptor profiles between Chinese cases of adult- and juvenile-onset myasthenia gravis using cell-based assays.
    J Neuroimmunol. 2020;349:577403.
    PubMed     Abstract available

  128. YAMAKAWA M, Mukaino A, Kimura A, Nagasako Y, et al
    Antibodies to the alpha3 subunit of the ganglionic-type nicotinic acetylcholine receptors in patients with autoimmune encephalitis.
    J Neuroimmunol. 2020;349:577399.
    PubMed     Abstract available

  129. YILMAZ V, Tuzun E, Durmus H, Oflazer P, et al
    The treatment effect on peripheral B cell markers in antibody positive myasthenia gravis patients.
    J Neuroimmunol. 2020;349:577402.
    PubMed     Abstract available

  130. HOWLETT-PRIETO Q, Langer C, Rezania K, Soliven B, et al
    Modulation of immune responses by bile acid receptor agonists in myasthenia gravis.
    J Neuroimmunol. 2020;349:577397.
    PubMed     Abstract available

  131. ZHONG H, Lu J, Jing S, Xi J, et al
    Low-dose rituximab lowers serum Exosomal miR-150-5p in AChR-positive refractory myasthenia gravis patients.
    J Neuroimmunol. 2020;348:577383.
    PubMed     Abstract available

  132. PARKHOUSE RME, Sciutto E, Hernandez M, Cortez MM, et al
    Extraparenchymal human neurocysticercosis induces autoantibodies against brain tubulin and MOG35-55 in cerebral spinal fluid.
    J Neuroimmunol. 2020;349:577389.
    PubMed     Abstract available

  133. DAS A, Khurshid S, Hayat S, Ahmed R, et al
    Glucocorticoid receptor gene polymorphisms in Guillain-Barre syndrome.
    J Neuroimmunol. 2020;348:577388.
    PubMed     Abstract available

  134. SIGNORIELLO E, Iardino P, Casertano S, De Lucia D, et al
    12-months prospective Pentraxin-3 and metabolomic evaluation in multiple sclerosis patients treated with glatiramer acetate.
    J Neuroimmunol. 2020;348:577385.
    PubMed     Abstract available

  135. ZOUVELOU V, Psimenou E
    AChR-and MuSK-positive myasthenia gravis: Double trouble.
    J Neuroimmunol. 2020;348:577364.
    PubMed     Abstract available

    August 2020
  136. ZHAN L, Fan M, Cai N, Cai B, et al
    Combination of autoimmune pancreatitis and peripheral neuropathy on an IgG4-related disease patient with 4 years following-up.
    J Neuroimmunol. 2020;348:577378.
    PubMed     Abstract available

  137. HEBERT J, Gros P, Lapointe S, Amtashar FS, et al
    Searching for autoimmune encephalitis: Beware of normal CSF.
    J Neuroimmunol. 2020;345:577285.
    PubMed     Abstract available

  138. LI X, Gao Q, Yang L, Han M, et al
    Matairesinol ameliorates experimental autoimmune uveitis by suppression of IRBP-specific Th17 cells.
    J Neuroimmunol. 2020;345:577286.
    PubMed     Abstract available

  139. JIAO L, Xiang Y, Li S, Zhang F, et al
    Efficacy of low dose rituximab in treatment-resistant CIDP with antibodies against NF-155.
    J Neuroimmunol. 2020;345:577280.
    PubMed     Abstract available

  140. ISMAIL S, Engin K, Ozan K, Mustafa C, et al
    Analysis of plasma protein biomarkers in childhood onset multiple sclerosis.
    J Neuroimmunol. 2020;348:577359.
    PubMed     Abstract available

  141. TRENOVA AG, Miteva LD, Stanilova SA
    Association between TNFA, IL10 and IL18 promoter gene variants and cognitive functions in patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2020;347:577357.
    PubMed     Abstract available

  142. SOTIROPOULOS MG, Chitnis T
    Opposing and potentially antagonistic effects of BMP and TGF-beta in multiple sclerosis: The "Yin and Yang" of neuro-immune Signaling.
    J Neuroimmunol. 2020;347:577358.
    PubMed     Abstract available

  143. IBRAHIM SH, El-Mehdawy KM, Seleem M, El-Sawalhi MM, et al
    Serum ROCK2, miR-300 and miR-450b-5p levels in two different clinical phenotypes of multiple sclerosis: Relation to patient disability and disease progression.
    J Neuroimmunol. 2020;347:577356.
    PubMed     Abstract available

  144. SALAVISA M, Paixao P, Ladeira AF, Mendes A, et al
    Prognostic value of kappa free light chains determination in first-ever multiple sclerosis relapse.
    J Neuroimmunol. 2020;347:577355.
    PubMed     Abstract available

    July 2020
  145. GARG D, Agarwal A, Bhagyawant R, Sikand TS, et al
    De novo nose-pinching stereotypy with somnolence: Clues to autoimmune encephalitis.
    J Neuroimmunol. 2020;347:577348.
    PubMed     Abstract available

  146. ACAR NP, Tuncer A, Ozkazanc D, Ozbay FG, et al
    An immunological and transcriptomics approach on differential modulation of NK cells in multiple sclerosis patients under interferon-beta1 and fingolimod therapy.
    J Neuroimmunol. 2020;347:577353.
    PubMed     Abstract available

  147. GHADERIAN S, Shomali N, Behravesh S, Danbaran GR, et al
    The emerging role of lncRNAs in multiple sclerosis.
    J Neuroimmunol. 2020;347:577347.
    PubMed     Abstract available

  148. STEFANOVIC M, Zivotic I, Stojkovic L, Dincic E, et al
    The association of genetic variants IL2RA rs2104286, IFI30 rs11554159 and IKZF3 rs12946510 with multiple sclerosis onset and severity in patients from Serbia.
    J Neuroimmunol. 2020;347:577346.
    PubMed     Abstract available

  149. CULLER G, Bachman E, VanHaerents S
    Paraclinical serum markers as aids in the diagnosis of autoimmune encephalitis.
    J Neuroimmunol. 2020;347:577324.
    PubMed     Abstract available

  150. CIARDI MR, Zingaropoli MA, Pasculli P, Perri V, et al
    The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia.
    J Neuroimmunol. 2020;346:577323.
    PubMed     Abstract available

  151. KENNEDY PGE, Graner MW, Walker D, Pointon T, et al
    Recombinant antibodies derived from laser captured single plasma cells of multiple sclerosis brain identified phage peptides which may be used as tools for characterizing intrathecal IgG response.
    J Neuroimmunol. 2020;347:577319.
    PubMed     Abstract available

  152. TIAN X, Chen C, Ma L, Wei R, et al
    Efficacy and safety of rituximab in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis.
    J Neuroimmunol. 2020;347:577317.
    PubMed     Abstract available

  153. HOUEN G, Heiden J, Trier NH, Draborg AH, et al
    Antibodies to Epstein-Barr virus and neurotropic viruses in multiple sclerosis and optic neuritis.
    J Neuroimmunol. 2020;346:577314.
    PubMed     Abstract available

  154. KEYVANI H, Zahednasab H, Aljanabi HAA, Asadi M, et al
    The role of human herpesvirus-6 and inflammatory markers in the pathogenesis of multiple sclerosis.
    J Neuroimmunol. 2020;346:577313.
    PubMed     Abstract available

    June 2020
  155. YETKIN MF, Mirza M
    Neutrophil to-lymphocyte ratio as a possible predictor of prognosis in recently diagnosed multiple sclerosis patients.
    J Neuroimmunol. 2020;346:577307.

  156. FARAHMAND F, Nourshahi M, Soleimani M, Rajabi H, et al
    The effect of 6 weeks of high intensity interval training on myelin biomarkers and demyelination in experimental autoimmune encephalomyelitis model.
    J Neuroimmunol. 2020;346:577306.
    PubMed     Abstract available

  157. FARZI MA, Ayromlou H, Jahanbakhsh N, Bavil PH, et al
    Guillain-Barre syndrome in a patient infected with SARS-CoV-2, a case report.
    J Neuroimmunol. 2020;346:577294.
    PubMed     Abstract available

  158. AL-NASERI MAS, Salman ED, Ad'hiah AH
    Relapsing-remitting multiple sclerosis: A profile of interleukine-1 gene cluster polymorphisms in Iraqi patients.
    J Neuroimmunol. 2020;346:577291.
    PubMed     Abstract available

  159. RYBERG B, Arvidsson A, Bergkvist M, Nilsson P, et al
    Limbic encephalitis in a neuroscientist: CASPR 2 antibody-associated disease after antigen exposure.
    J Neuroimmunol. 2020;343:577231.
    PubMed     Abstract available

  160. JUNG KO, Moon HJ
    A case of NMDAR encephalitis treated in the third trimester - novel arterial spin labeling findings and a review of literature.
    J Neuroimmunol. 2020;343:577235.
    PubMed     Abstract available

  161. AKAISHI T, Takahashi T, Fujihara K, Misu T, et al
    Risk factors of attacks in neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2020;343:577236.
    PubMed     Abstract available

  162. GONZALEZ-ALVARADO MN, Rotger C, Berger L, London B, et al
    Functional role of endogenous Kv1.4 in experimental demyelination.
    J Neuroimmunol. 2020;343:577227.
    PubMed     Abstract available

  163. NAJJAR E, Staun-Ram E, Volkowich A, Miller A, et al
    Dimethyl fumarate promotes B cell-mediated anti-inflammatory cytokine profile in B and T cells, and inhibits immune cell migration in patients with MS.
    J Neuroimmunol. 2020;343:577230.
    PubMed     Abstract available

  164. SUN H, Ma X, Sun X, Wu L, et al
    Is transient hyperCKemia a new feature of neuromyelitis optica spectrum disorders? A retrospective study in 439 patients.
    J Neuroimmunol. 2020;343:577228.
    PubMed     Abstract available

  165. AHARONI R, Eilam R, Schottlender N, Radomir L, et al
    Glatiramer acetate increases T- and B -regulatory cells and decreases granulocyte-macrophage colony-stimulating factor (GM-CSF) in an animal model of multiple sclerosis.
    J Neuroimmunol. 2020;345:577281.
    PubMed     Abstract available

    May 2020
  166. RACKE MK, Newsome SD
    Multiple sclerosis and COVID-19: A great opportunity for databases promoting research and collaboration.
    J Neuroimmunol. 2020 May 31:577283. doi: 10.1016/j.jneuroim.2020.577283.

  167. CHIARINI M, Paghera S, Moratto D, Rossi N, et al
    Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection.
    J Neuroimmunol. 2020;345:577282.
    PubMed     Abstract available

  168. LI Y, Guptill JT, Russo MA, Howard JF Jr, et al
    Imbalance in T follicular helper cells producing IL-17 promotes pro-inflammatory responses in MuSK antibody positive myasthenia gravis.
    J Neuroimmunol. 2020;345:577279.
    PubMed     Abstract available

  169. GRIFFITH SP, Malpas CB, Alpitsis R, O'Brien TJ, et al
    The neuropsychological spectrum of anti-LGI1 antibody mediated autoimmune encephalitis.
    J Neuroimmunol. 2020;345:577271.
    PubMed     Abstract available

  170. MAURICE C, Khoja L, Morgan E, Mason WP, et al
    Guillain-Barre Syndrome following a series of novel therapies adapting the gold-standard in the era of immune priming.
    J Neuroimmunol. 2020;346:577267.
    PubMed     Abstract available

  171. KAPADIA RK, Ney DE, Hannan M, Farley M, et al
    Glial fibrillary acidic protein (GFAP) associated autoimmune meningoencephalitis in a patient receiving nivolumab.
    J Neuroimmunol. 2020;344:577259.
    PubMed     Abstract available

    April 2020
  172. KEFALOPOULOU ZM, Liossis SN, Sagona T, Veltsista D, et al
    An ischemic stroke as the presenting manifestation of rapidly progressive primary angiitis of central nervous system in a 17-year-old boy.
    J Neuroimmunol. 2020;341:577190.
    PubMed     Abstract available

  173. LI X, Guo Q, Zheng Z, Wang X, et al
    Immune-mediated epilepsy with GAD65 antibodies.
    J Neuroimmunol. 2020;341:577189.
    PubMed     Abstract available

  174. BERNARDO F, Rebordao L, Rego A, Machado S, et al
    Stiff person spectrum disorders: An illustrative case series of their phenotypic and antibody diversity.
    J Neuroimmunol. 2020;341:577192.
    PubMed     Abstract available

  175. SHIBUYA K, Tsuneyama A, Misawa S, Sekiguchi Y, et al
    Different distribution of demyelination in chronic inflammatory demyelinating polyneuropathy subtypes.
    J Neuroimmunol. 2020;341:577170.
    PubMed     Abstract available

  176. PREVEZIANOU A, Tzartos JS, Dagklis IE, Bentenidi E, et al
    Paraneoplastic cerebellar degeneration in a patient with breast cancer associated with carbonic anhydrase-related protein VIII autoantibodies.
    J Neuroimmunol. 2020;344:577242.
    PubMed     Abstract available

  177. ANEJA J, Kuppili PP, Paul K, Panda S, et al
    Antiphospholipid syndrome presenting as treatment resistant bipolar disorder and thrombocytopenia in a young male.
    J Neuroimmunol. 2020;343:577238.
    PubMed     Abstract available

  178. BOULLERNE AI, Adami GR, Schwartz JL, Skias D, et al
    Deep DNA metagenomic sequencing reveals oral microbiome divergence between monozygotic twins discordant for multiple sclerosis severity.
    J Neuroimmunol. 2020;343:577237.
    PubMed     Abstract available

  179. PARKHOUSE RME, Carpio A, Cortez MM, von Kriegsheim A, et al
    Anti-brain protein autoantibodies are detectable in extraparenchymal but not parenchymal neurocysticercosis.
    J Neuroimmunol. 2020;344:577234.
    PubMed     Abstract available

    March 2020
  180. PRABHAT N, Chakravarty K, Pattnaik SN, Takkar A, et al
    Systemic lupus erythematosus with autoimmune neurological manifestations in a carrier of chronic granulomatous disease - a rare presentation.
    J Neuroimmunol. 2020;343:577229.
    PubMed     Abstract available

  181. MUKE I, Sprenger A, Bobylev I, Wiemer V, et al
    Ultrastructural characterization of mitochondrial damage in experimental autoimmune neuritis.
    J Neuroimmunol. 2020;343:577218.
    PubMed     Abstract available

  182. BOLDRINI VO, Brandao CO, Pimentel MLV, Vidal A, et al
    Massive activity of cytotoxic cells during refractory Neuromyelitis Optica spectrum disorder.
    J Neuroimmunol. 2020;340:577148.
    PubMed     Abstract available

  183. AKAISHI T, Takahashi T, Himori N, Fujihara K, et al
    Serum AQP4-IgG level is associated with the phenotype of the first attack in neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2020;340:577168.
    PubMed     Abstract available

  184. URIBE-SAN-MARTIN R, Ciampi E, Cruz JP, Vasquez M, et al
    Refractory epilepsy associated with anti-ribosomal P antibodies successfully treated with topiramate.
    J Neuroimmunol. 2020;340:577144.
    PubMed     Abstract available

  185. MADDISON P, Gozzard P, Sadalage G, Ambrose PA, et al
    Neuronal antibody detection and improved lung cancer prediction in Lambert-Eaton myasthenic syndrome.
    J Neuroimmunol. 2020;340:577149.
    PubMed     Abstract available

  186. PEDAPATI R, Bhatia R, Singh N, Bali P, et al
    Anti-myelin oligodendrocyte glycoprotein antibody associated disease spectrum - A north Indian tertiary care centre experience and review of literature.
    J Neuroimmunol. 2020;340:577143.
    PubMed     Abstract available

  187. MACCHI ZA, Kleinschmidt-DeMasters BK, Orjuela KD, Pastula DM, et al
    Glioblastoma as an autoimmune limbic encephalitis mimic: A case and review of the literature.
    J Neuroimmunol. 2020;342:577214.
    PubMed     Abstract available

  188. PETKOVIC F, Lazzarino GP, Engblom D, Blomqvist A, et al
    IL-6R expressed on CNS vascular endothelial cells contributes to the development of experimental autoimmune encephalomyelitis in mice.
    J Neuroimmunol. 2020;342:577211.
    PubMed     Abstract available

  189. TAHMASEBIVAND M, Mousavi SR, Khorrami M, Ayromlou H, et al
    miR-504 expression level is increased in multiple sclerosis patients responder to interferon-beta.
    J Neuroimmunol. 2020;342:577212.
    PubMed     Abstract available

  190. MCGILL MM, Sabikunnahar B, Fang Q, Teuscher C, et al
    The sex-specific role of p38 MAP kinase in CNS autoimmunity is regulated by estrogen receptor alpha.
    J Neuroimmunol. 2020;342:577209.

    February 2020
  191. PEREZ CA, Shah EG, Butler IJ
    Mercury-induced autoimmunity: Report of two adolescent siblings with Morvan syndrome "plus" and review of the literature.
    J Neuroimmunol. 2020;342:577197.
    PubMed     Abstract available

  192. LISAK RP, Nedelkoska L, Benjamins JA
    Sigma-1 receptor agonists as potential protective therapies in multiple sclerosis.
    J Neuroimmunol. 2020;342:577188.
    PubMed     Abstract available

  193. OGATA H, Isobe N, Zhang X, Yamasaki R, et al
    Unique HLA haplotype associations in IgG4 anti-neurofascin 155 antibody-positive chronic inflammatory demyelinating polyneuropathy.
    J Neuroimmunol. 2020;339:577139.
    PubMed     Abstract available

  194. SHI Z, Qiu Y, Wang J, Fang Y, et al
    Dysbiosis of gut microbiota in patients with neuromyelitis optica spectrum disorders: A cross sectional study.
    J Neuroimmunol. 2020;339:577126.
    PubMed     Abstract available

  195. BRILL L, Vaknin-Dembinsky A, Zveik O, Haham N, et al
    MIF -173G/C polymorphism is associated with NMO disease severity.
    J Neuroimmunol. 2020;339:577120.
    PubMed     Abstract available

  196. GARIMELLA V, McVoy JS, Oh U
    The contribution of cyclophilin A to immune-mediated central nervous system inflammation.
    J Neuroimmunol. 2020;339:577118.
    PubMed     Abstract available

  197. ZHANG W, Dong M, Dong H, Wang W, et al
    Reduced sarcolemmal aquaporin 4 expression can support the differential diagnosis of neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2020;339:577121.
    PubMed     Abstract available

  198. GOMES NA, Silva PC, Teixeira YT, Eufrazio P, et al
    HLA-G Ins/Del polymorphism and +3142C/G SNP are not related to neuromyelitis optica spectrum disorder (NMOSD) development, disability status or anti-aquaporin 4 presence in Brazilian patients.
    J Neuroimmunol. 2020;339:577112.
    PubMed     Abstract available

  199. NYSTAD AE, Lereim RR, Wergeland S, Oveland E, et al
    Fingolimod downregulates brain sphingosine-1-phosphate receptor 1 levels but does not promote remyelination or neuroprotection in the cuprizone model.
    J Neuroimmunol. 2020;339:577091.
    PubMed     Abstract available

  200. HABIB R, Ocklenburg S, Hoffjan S, Haghikia A, et al
    Association between shorter leukocyte telomeres and multiple sclerosis.
    J Neuroimmunol. 2020;341:577187.
    PubMed     Abstract available

  201. TRAN GT, Hodgkinson SJ, Carter N, Verma ND, et al
    Autoantigen specific IL-2 activated CD4(+)CD25(+)T regulatory cells inhibit induction of experimental autoimmune neuritis.
    J Neuroimmunol. 2020;341:577186.
    PubMed     Abstract available

    January 2020
  202. SHAHIDI SH, Kordi MR, Rajabi H, Malm C, et al
    Exercise modulates the levels of growth inhibitor genes before and after multiple sclerosis.
    J Neuroimmunol. 2020;341:577172.
    PubMed     Abstract available

  203. HEMING M, Lohmann L, Schulte-Mecklenbeck A, Brix T, et al
    Leukocyte profiles in blood and CSF distinguish neurosarcoidosis from multiple sclerosis.
    J Neuroimmunol. 2020;341:577171.
    PubMed     Abstract available

  204. SAHAMI-FARD MH, Mozhdeh M, Izadpanah F, Kashani HH, et al
    Interleukin 7 receptor T244I polymorphism and the multiple sclerosis susceptibility: a meta-analysis.
    J Neuroimmunol. 2020;341:577166.
    PubMed     Abstract available

  205. LIU S, Zhang X, Wang J, Yang H, et al
    Analysis of plasma autoantibodies for inflammatory cytokines in patients with first-episode schizophrenia among a Chinese population.
    J Neuroimmunol. 2020;341:577165.
    PubMed     Abstract available

  206. ZHANG Y, Zhang Q, Shi Z, Chen H, et al
    Sexual dysfunction in patients with neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2020;338:577093.
    PubMed     Abstract available

  207. AGASING AM, Gawde S, Kumar G, Turner E, et al
    B cell function impacts the efficacy of IFN-beta therapy in EAE.
    J Neuroimmunol. 2020;338:577106.
    PubMed     Abstract available

  208. BLACKBURN K, Wang C, Greenberg B
    Two cases of aquaporin-4 positive neuromyelitis optica associated with T-cell lymphoma.
    J Neuroimmunol. 2020;338:577092.
    PubMed     Abstract available

  209. DAS NEVES SP, Santos G, Barros C, Pereira DR, et al
    Enhanced cognitive performance in experimental autoimmune encephalomyelitis mice treated with dimethyl fumarate after the appearance of disease symptoms.
    J Neuroimmunol. 2020;340:577163.
    PubMed     Abstract available

  210. PANDYA D, Hellerslia V, Gettings E
    Acquired factor VIII inhibitor in a patient with multiple sclerosis treated with interferon beta-1a.
    J Neuroimmunol. 2020;340:577146.
    PubMed     Abstract available

  211. HAKANSSON I, Ernerudh J, Vrethem M, Dahle C, et al
    Complement activation in cerebrospinal fluid in clinically isolated syndrome and early stages of relapsing remitting multiple sclerosis.
    J Neuroimmunol. 2020;340:577147.
    PubMed     Abstract available

    December 2019
  212. NOVIKOVA NS, Diatlova AS, Derevtsova KZ, Korneva EA, et al
    Corrigendum to "Tuftsin-phosphorylcholine attenuate experimental autoimmune encephalomyelitis" [J Neuroimmunol. 2019 Dec 15;337:577070. doi: 10.1016/j.jneuroim.2019.577070. Epub 2019 Oct 24].
    J Neuroimmunol. 2019 Dec 27:577137. doi: 10.1016/j.jneuroim.2019.577137.

  213. JOOB B, Wiwanitkit V
    Tumor necrosis factor alpha -863C/A polymorphism and Guillain-Barre Syndrome.
    J Neuroimmunol. 2019;339:577140.

  214. LAZARIDIS K, Baltatzidou V, Tektonidis N, Tzartos SJ, et al
    Antigen-specific immunoadsorption of MuSK autoantibodies as a treatment of MuSK-induced experimental autoimmune myasthenia gravis.
    J Neuroimmunol. 2019;339:577136.
    PubMed     Abstract available

  215. SHIMASAKI C, Frye RE, Trifiletti R, Cooperstock M, et al
    Evaluation of the Cunningham Panel in pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS): Changes in antineuronal antibody titers parallel changes
    J Neuroimmunol. 2019;339:577138.
    PubMed     Abstract available

  216. UZAWA A, Ozawa Y, Yasuda M, Oda F, et al
    Increased serum acetylcholine receptor alpha1 subunit protein in anti-acetylcholine receptor antibody-positive myasthenia gravis.
    J Neuroimmunol. 2019;339:577125.
    PubMed     Abstract available

  217. PEREZ CA, Agyei P, Gogia B, Harrison R, et al
    Overlapping autoimmune syndrome: A case of concomitant anti-NMDAR encephalitis and myelin oligodendrocyte glycoprotein (MOG) antibody disease.
    J Neuroimmunol. 2019;339:577124.
    PubMed     Abstract available

  218. CAVALLA P, Caropreso P, Limoncelli S, Bosa C, et al
    Kappa free light chains index in the differential diagnosis of Multiple Sclerosis from Neuromyelitis optica spectrum disorders and other immune-mediated central nervous system disorders.
    J Neuroimmunol. 2019;339:577122.
    PubMed     Abstract available

    November 2019
  219. MONTEIRO A, Rosado P, Rosado L, Fonseca AM, et al
    Alterations in circulating T cell functional subpopulations in interferon-beta treated multiple sclerosis patients: A pilot study.
    J Neuroimmunol. 2019;339:577113.
    PubMed     Abstract available

  220. MARCUCCI SB, Obeidat AZ
    EBNA1, EBNA2, and EBNA3 link Epstein-Barr virus and hypovitaminosis D in multiple sclerosis pathogenesis.
    J Neuroimmunol. 2019;339:577116.
    PubMed     Abstract available

  221. GLENN JD, Pantoja IM, Caturegli P, Whartenby KA, et al
    MYMD-1, a novel alkaloid compound, ameliorates the course of experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2019;339:577115.
    PubMed     Abstract available

  222. AMMITZBOLL C, von Essen MR, Chow HH, McWilliam O, et al
    MAIT cell subtypes in multiple sclerosis.
    J Neuroimmunol. 2019;339:577117.
    PubMed     Abstract available

  223. SPANIER JA, Nashold FE, Nelson CD, Praska CE, et al
    Vitamin D3-mediated resistance to a multiple sclerosis model disease depends on myeloid cell 1,25-dihydroxyvitamin D3 synthesis and correlates with increased CD4(+) T cell CTLA-4 expression.
    J Neuroimmunol. 2019;338:577105.
    PubMed     Abstract available

  224. NASI M, Bianchini E, De Biasi S, Gibellini L, et al
    Increased plasma levels of mitochondrial DNA and pro-inflammatory cytokines in patients with progressive multiple sclerosis.
    J Neuroimmunol. 2019;338:577107.
    PubMed     Abstract available

  225. GAETANI L, Di Carlo M, Brachelente G, Valletta F, et al
    Cerebrospinal fluid free light chains compared to oligoclonal bands as biomarkers in multiple sclerosis.
    J Neuroimmunol. 2019;339:577108.
    PubMed     Abstract available

  226. ARRU G, Sechi E, Mariotto S, Zarbo IR, et al
    Antibody response against HERV-W in patients with MOG-IgG associated disorders, multiple sclerosis and NMOSD.
    J Neuroimmunol. 2019;338:577110.
    PubMed     Abstract available

    October 2019
  227. CAO Q, Zheng C, Xie Z, Liu L, et al
    The change of PD1, PDL1 in experimental autoimmune encephalomyelitis treated by 1,25(OH)2D3.
    J Neuroimmunol. 2019;338:577079.
    PubMed     Abstract available

  228. KOLIC I, Stojkovic L, Dincic E, Jovanovic I, et al
    Expression of LEP, LEPR and PGC1A genes is altered in peripheral blood mononuclear cells of patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2019;338:577090.
    PubMed     Abstract available

  229. NOVIKOVA NS, Diatlova AS, Derevtsova KZ, Korneva EA, et al
    Tuftsin-phosphorylcholine attenuate experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2019;337:577070.
    PubMed     Abstract available

  230. HAN J, Zhang J, Li M, Zhang Y, et al
    A novel MuSK cell-based myasthenia gravis diagnostic assay.
    J Neuroimmunol. 2019;337:577076.
    PubMed     Abstract available

  231. BASNYAT P, Sumelahti ML, Lehtimaki T, Elovaara I, et al
    Gene expression profiles of TNF-like cytokine 1A (TL1A) and its receptors death receptor 3 (DR3) and decoy receptor 3 (DcR3) in multiple sclerosis.
    J Neuroimmunol. 2019;335:577020.
    PubMed     Abstract available

  232. SOUTO EB, Lima B, Campos JR, Martins-Gomes C, et al
    Myasthenia gravis: State of the art and new therapeutic strategies.
    J Neuroimmunol. 2019;337:577080.
    PubMed     Abstract available

  233. KAMMEYER R, Piquet AL
    Multiple co-existing antibodies in autoimmune encephalitis: A case and review of the literature.
    J Neuroimmunol. 2019;337:577084.
    PubMed     Abstract available

  234. PETERSEN ER, Ammitzboll C, Sondergaard HB, Oturai AB, et al
    Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis.
    J Neuroimmunol. 2019;337:577085.
    PubMed     Abstract available

    September 2019
  235. RANJBAR R, Karampoor S, Jalilian FA
    The protective effect of Helicobacter Pylori infection on the susceptibility of multiple sclerosis.
    J Neuroimmunol. 2019;337:577069.
    PubMed     Abstract available

  236. BOYAO Y, Mengjiao S, Caicai B, Xiaoling L, et al
    Dynamic expression of autophagy-related factors in autoimmune encephalomyelitis and exploration of curcumin therapy.
    J Neuroimmunol. 2019;337:577067.
    PubMed     Abstract available

  237. KURTUNCU M, Yilmaz V, Akcay HI, Turkoglu R, et al
    Impact of fingolimod on CD4+ T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients.
    J Neuroimmunol. 2019;337:577065.
    PubMed     Abstract available

  238. CARLOS CE, Gianfranco CS, Miguel CC, Crist EA, et al
    Is there a significant association between tumor necrosis factor alpha -863C/A polymorphism and the development of Guillain-Barre Syndrome?
    J Neuroimmunol. 2019;337:577064.

  239. ABDEL-DAYEM MA, Shaker ME, Gameil NM
    Impact of interferon beta-1b, interferon beta-1a and fingolimod therapies on serum interleukins-22, 32alpha and 34 concentrations in patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2019;337:577062.
    PubMed     Abstract available

  240. AFSHAR B, Khalifehzadeh-Esfahani Z, Seyfizadeh N, Rezaei Danbaran G, et al
    The role of immune regulatory molecules in multiple sclerosis.
    J Neuroimmunol. 2019;337:577061.
    PubMed     Abstract available

  241. MARGONI M, Carotenuto A
    Very late-onset recurrent myelitis in a patient diagnosed with antiphospholipid syndrome: A puzzle of autoimmunity.
    J Neuroimmunol. 2019;337:577051.
    PubMed     Abstract available

  242. BROOKS PT, Bell JA, Bejcek CE, Malik A, et al
    An antibiotic depleted microbiome drives severe Campylobacter jejuni-mediated Type 1/17 colitis, Type 2 autoimmunity and neurologic sequelae in a mouse model.
    J Neuroimmunol. 2019;337:577048.
    PubMed     Abstract available

    August 2019
  243. LIANG H, Gao W, Liu X, Liu J, et al
    The GTF2I rs117026326 polymorphism is associated with neuromyelitis optica spectrum disorder but not with multiple sclerosis in a Northern Han Chinese population.
    J Neuroimmunol. 2019;337:577045.
    PubMed     Abstract available

  244. ZAROBKIEWICZ MK, Kowalska W, Halczuk P, Wos J, et al
    RORgammaT is overexpressed in iNKT and gammadelta T cells during relapse in relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2019;337:577046.
    PubMed     Abstract available

  245. ZHANG G, Wang Q, Song Y, Cheng P, et al
    Intravenous immunoglobulin promotes the proliferation of CD4(+)CD25(+) Foxp3(+) regulatory T cells and the cytokines secretion in patients with Guillain-Barre syndrome in vitro.
    J Neuroimmunol. 2019;336:577042.
    PubMed     Abstract available

  246. SVEINSSON O, Piehl F, Aspegren O, Hietala MA, et al
    Successful combined treatment with thymectomy, rituximab and tocilizumab for severe thymoma-associated multi autoimmune syndrome.
    J Neuroimmunol. 2019;336:577028.
    PubMed     Abstract available

  247. DURCAN R, Heffron C, Sweeney B
    Natalizumab induced cutaneous sarcoidosis-like reaction.
    J Neuroimmunol. 2019;333:476955.
    PubMed     Abstract available

  248. KAUSHANSKY N, Kaminitz A, Allouche-Arnon H, Ben-Nun A, et al
    Modulation of MS-like disease by a multi epitope protein is mediated by induction of CD11c(+)CD11b(+)Gr1(+) myeloid-derived dendritic cells.
    J Neuroimmunol. 2019;333:476953.
    PubMed     Abstract available

    July 2019
  249. NAKAMURA Y, Igaki K, Uga K, Shibata A, et al
    Pharmacological evaluation of TAK-828F, a novel orally available RORgammat inverse agonist, on murine chronic experimental autoimmune encephalomyelitis model.
    J Neuroimmunol. 2019;335:577016.
    PubMed     Abstract available

  250. NOSADINI M, Toldo I, Tascini B, Bien CG, et al
    LGI1 and CASPR2 autoimmunity in children: Systematic literature review and report of a young girl with Morvan syndrome.
    J Neuroimmunol. 2019;335:577008.
    PubMed     Abstract available

  251. DEL FABBRO L, de Gomes MG, Souza LC, Goes AR, et al
    Chrysin suppress immune responses and protects from experimental autoimmune encephalomyelitis in mice.
    J Neuroimmunol. 2019;335:577007.
    PubMed     Abstract available

  252. NICOLETTI F, Mazzon E, Fagone P, Mangano K, et al
    Prevention of clinical and histological signs of MOG-induced experimental allergic encephalomyelitis by prolonged treatment with recombinant human EGF.
    J Neuroimmunol. 2019;332:224-232.
    PubMed     Abstract available

  253. DZANGUE-TCHOUPOU G, Allenbach Y, Preusse C, Stenzel W, et al
    Mass cytometry reveals an impairment of B cell homeostasis in anti-synthetase syndrome.
    J Neuroimmunol. 2019;332:212-215.
    PubMed     Abstract available

  254. JAZEBI N, Rodrigo S, Gogia B, Shawagfeh A, et al
    Anti-glutamic acid decarboxylase (GAD) positive cerebellar Ataxia with transitioning to progressive encephalomyelitis with rigidity and myoclonus (PERM), responsive to immunotherapy: A case report and review of literature.
    J Neuroimmunol. 2019;332:135-137.
    PubMed     Abstract available

  255. ENRIQUEZ CAG, Espiritu AI, Pasco PMD
    Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review.
    J Neuroimmunol. 2019;332:126-134.
    PubMed     Abstract available

  256. NEEDHAM EJ, Helmy A, Zanier ER, Jones JL, et al
    The immunological response to traumatic brain injury.
    J Neuroimmunol. 2019;332:112-125.
    PubMed     Abstract available

  257. FREUND B, Ritzl EK
    A review of EEG in anti-NMDA receptor encephalitis.
    J Neuroimmunol. 2019;332:64-68.
    PubMed     Abstract available

  258. CAVALIERE E, Nosadini M, Pelizza MF, Ventura G, et al
    Anti-NMDAR encephalitis preceded by non-herpetic central nervous system infection: Systematic literature review and first case of tick-borne encephalitis triggering anti-NMDAR encephalitis.
    J Neuroimmunol. 2019;332:1-7.
    PubMed     Abstract available

    June 2019
  259. KIMURA A, Takemura M, Yamamoto Y, Hayashi Y, et al
    Cytokines and biological markers in autoimmune GFAP astrocytopathy: The potential role for pathogenesis and therapeutic implications.
    J Neuroimmunol. 2019;334:576999.
    PubMed     Abstract available

  260. NICKEL M, Eid F, Jukkola P, Gu C, et al
    Copper chelation and autoimmunity differentially impact myelin in the hippocampal-prefrontal circuit.
    J Neuroimmunol. 2019;334:576998.
    PubMed     Abstract available

  261. LAMPORT AC, Chedrawe M, Nichols M, Robertson GS, et al
    Experimental autoimmune encephalomyelitis accelerates remyelination after lysophosphatidylcholine-induced demyelination in the corpus callosum.
    J Neuroimmunol. 2019;334:576995.
    PubMed     Abstract available

  262. IMITOLA J
    Regenerative neuroimmunology: The impact of immune and neural stem cell interactions for translation in neurodegeneration and repair.
    J Neuroimmunol. 2019;331:1-3.

  263. ANTEL JP, Lin YH, Cui QL, Pernin F, et al
    Immunology of oligodendrocyte precursor cells in vivo and in vitro.
    J Neuroimmunol. 2019;331:28-35.
    PubMed     Abstract available

  264. ZORLU N, Hoffjan S, Haghikia A, Deyneko IV, et al
    Evaluation of variation in genes of the arylhydrocarbon receptor pathway for an association with multiple sclerosis.
    J Neuroimmunol. 2019;334:576979.
    PubMed     Abstract available

    May 2019
  265. KOCH MW, Liu WQ, Camara-Lemarroy C, Zhang Y, et al
    Domperidone-induced elevation of serum prolactin levels and immune response in multiple sclerosis.
    J Neuroimmunol. 2019;334:576974.
    PubMed     Abstract available

  266. ZURAWSKA A, Mycko MP, Selmaj KW
    Circular RNAs as a novel layer of regulatory mechanism in multiple sclerosis.
    J Neuroimmunol. 2019;334:576971.
    PubMed     Abstract available

  267. RASOOLI TEHRANI A, Gholipour S, Sharifi R, Yadegari S, et al
    Plasma levels of CTRP-3, CTRP-9 and apelin in women with multiple sclerosis.
    J Neuroimmunol. 2019;333:576968.
    PubMed     Abstract available

  268. TOMESCU-BACIU A, Johansen JN, Holmoy T, Greiff V, et al
    Persistence of intrathecal oligoclonal B cells and IgG in multiple sclerosis.
    J Neuroimmunol. 2019;333:576966.
    PubMed     Abstract available

  269. SHOU J, Peng J, Zhao Z, Huang X, et al
    CCL26 and CCR3 are associated with the acute inflammatory response in the CNS in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2019;333:576967.
    PubMed     Abstract available

  270. XU H, Zhang M, Li XL, Li H, et al
    Corrigendum to: "low and high doses of ursolic acid ameliorate experimental autoimmune myasthenia gravis through different pathways" [Journal of Neuroimmunology 281 (2015) 61-67].
    J Neuroimmunol. 2019;330:181-183.

  271. QU Z, Zheng N, Wei Y, Chen Y, et al
    Effect of cornel iridoid glycoside on microglia activation through suppression of the JAK/STAT signalling pathway.
    J Neuroimmunol. 2019;330:96-107.
    PubMed     Abstract available

  272. SHOUMAN K, Prieto PG, Stino AM, Lisak RP, et al
    Serum Creatine Kinase in Patients with Neuromyelitis Optica Spectrum Disorder.
    J Neuroimmunol. 2019;330:87-89.
    PubMed     Abstract available

  273. DENG B, Yu H, Liu X, Yu X, et al
    Reduced dosage rituximab in the treatment of anti-N-methyl-d-aspartate receptor encephalitis: An observation study in Chinese patients.
    J Neuroimmunol. 2019;330:81-86.
    PubMed     Abstract available

  274. KELLER CW, Quast I, Dalakas MC, Lunemann JD, et al
    IVIG efficacy in CIDP patients is not associated with terminal complement inhibition.
    J Neuroimmunol. 2019;330:23-27.
    PubMed     Abstract available

  275. KAMO H, Ueno Y, Sugiyama M, Miyamoto N, et al
    Pontine hemorrhage accompanied by neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2019;330:19-22.
    PubMed     Abstract available

  276. MONTEIRO C, Fernandes G, Kasahara TM, Barros PO, et al
    The expansion of circulating IL-6 and IL-17-secreting follicular helper T cells is associated with neurological disabilities in neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2019;330:12-18.
    PubMed     Abstract available

  277. SPENCE S, Ng D, Casault C
    Atypical presentation of fulminant primary central nervous system angiitis.
    J Neuroimmunol. 2019;330:1-4.
    PubMed     Abstract available

  278. BRIANI C, Salvalaggio A, Ruiz M, Cacciavillani M, et al
    Tongue tremor in neurofascin-155 IgG4 seropositive chronic inflammatory polyradiculoneuropathy.
    J Neuroimmunol. 2019;330:178-180.
    PubMed     Abstract available

  279. YOON L, Kim BR, Kim HY, Kwak MJ, et al
    Clinical characterization of anti-GQ1b antibody syndrome in Korean children.
    J Neuroimmunol. 2019;330:170-173.
    PubMed     Abstract available

  280. JING S, Lu J, Song J, Luo S, et al
    Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis.
    J Neuroimmunol. 2019;332:216-223.
    PubMed     Abstract available

  281. LOVETT-RACKE AE, Gormley M, Liu Y, Yang Y, et al
    B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients.
    J Neuroimmunol. 2019;332:187-197.
    PubMed     Abstract available

  282. BORHANI-HAGHIGHI M, Mohamadi Y
    The therapeutic effect of platelet-rich plasma on the experimental autoimmune encephalomyelitis mice.
    J Neuroimmunol. 2019;333:476958.
    PubMed     Abstract available

    April 2019
  283. SETIADI AF, Abbas AR, Jeet S, Wong K, et al
    IL-17A is associated with the breakdown of the blood-brain barrier in relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2019;332:147-154.
    PubMed     Abstract available

  284. KIRA JI, Isobe N
    Helicobacter pylori infection and demyelinating disease of the central nervous system.
    J Neuroimmunol. 2019;329:14-19.
    PubMed     Abstract available

  285. KIMURA A, Takekoshi A, Yoshikura N, Hayashi Y, et al
    Clinical characteristics of autoimmune GFAP astrocytopathy.
    J Neuroimmunol. 2019;332:91-98.
    PubMed     Abstract available

  286. MADDISON P, Sadalage G, Ambrose PA, Jacob S, et al
    False-positive acetylcholine receptor antibody results in patients without myasthenia gravis.
    J Neuroimmunol. 2019;332:69-72.
    PubMed     Abstract available

  287. SUN Y, Jing Y, Huang M, Ma J, et al
    The PD-1/PD-Ls pathway is up-regulated during the suppression of experimental autoimmune encephalomyelitis treated by Astragalus polysaccharides.
    J Neuroimmunol. 2019;332:78-90.
    PubMed     Abstract available

    March 2019
  288. SCHLIFFKE S, Carambia A, Akyuz N, Thiele B, et al
    T-cell repertoire profiling by next-generation sequencing reveals tissue migration dynamics of TRBV13-family clonotypes in a common experimental autoimmune encephalomyelitis mouse model.
    J Neuroimmunol. 2019;332:49-56.
    PubMed     Abstract available

  289. VAITAITIS GM, Yussman MG, Wagner DH Jr
    A CD40 targeting peptide prevents severe symptoms in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2019;332:8-15.
    PubMed     Abstract available

  290. ROJC B, Podnar B, Graus F
    A case of recurrent MOG antibody positive bilateral optic neuritis and anti-NMDAR encephalitis: Different biological evolution of the two associated antibodies.
    J Neuroimmunol. 2019;328:86-88.
    PubMed     Abstract available

  291. GARG M, Mittal J, Gupta P
    Association of typhoid fever with anti-NMDAR encephalitis in a young child.
    J Neuroimmunol. 2019;328:76-77.

  292. GASTALDI M, Arbasino C, Dallocchio C, Diamanti L, et al
    NMDAR encephalitis presenting as akinesia in a patient with Parkinson disease.
    J Neuroimmunol. 2019;328:35-37.
    PubMed     Abstract available

  293. VOO VTF, O'Brien T, Butzkueven H, Monif M, et al
    The role of vitamin D and P2X7R in multiple sclerosis.
    J Neuroimmunol. 2019;330:159-169.
    PubMed     Abstract available

  294. HILLIS JM, Mateen FJ
    Neuromyelitis optica after splenectomy: A secondary autoimmune phenomenon.
    J Neuroimmunol. 2019;330:152-154.
    PubMed     Abstract available

  295. CIERNY D, Michalik J, Dubovan P, Skerenova M, et al
    The association of rs703842 variants in CYP27B1 with multiple sclerosis susceptibility is influenced by the HLA-DRB1*15:01 allele in Slovaks.
    J Neuroimmunol. 2019;330:123-129.
    PubMed     Abstract available

  296. ANNUNZIATA P, Masi G, Cioni C
    Association of circulating anti-CD64 IgM levels with favourable long-term clinical outcomes in multiple sclerosis patients.
    J Neuroimmunol. 2019;330:130-135.
    PubMed     Abstract available

  297. AMMITZBOLL C, Bornsen L, Petersen ER, Oturai AB, et al
    Perfluorinated substances, risk factors for multiple sclerosis and cellular immune activation.
    J Neuroimmunol. 2019;330:90-95.
    PubMed     Abstract available

    February 2019
  298. ZHANG DQ, Deng Y, Zhang LJ, Li LM, et al
    Elevated resistin levels may regulate high mobility group box 1 expression in Guillain-Barre syndrome.
    J Neuroimmunol. 2019;330:59-66.
    PubMed     Abstract available

  299. DA SILVA BERNARDES M, Antao Paiva CL, Ribeiro Paradela E, Papais Alvarenga M, et al
    Familial multiple sclerosis in a Brazilian sample: Is HLA-DR15 involved in susceptibility to the disease?
    J Neuroimmunol. 2019;330:74-80.
    PubMed     Abstract available

  300. ZAROBKIEWICZ MK, Kowalska W, Rolinski J, Bojarska-Junak AA, et al
    gammadelta T lymphocytes in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2019;330:67-73.
    PubMed     Abstract available

  301. AL-TEMAIMI R, Cherian P, Abu-Farha M, Alroughani R, et al
    Angiopoietin-like proteins in multiple sclerosis.
    J Neuroimmunol. 2019;330:31-34.
    PubMed     Abstract available

  302. GILLINDER L, Papacostas J, Dionisio S
    Electroclinical insights into autoimmune epilepsy.
    J Neuroimmunol. 2019;330:44-47.
    PubMed     Abstract available

  303. SAVAGE SA, Irani SR, Leite MI, Zeman AZ, et al
    NMDA receptor antibody encephalitis presenting as Transient Epileptic Amnesia.
    J Neuroimmunol. 2019;327:41-43.
    PubMed     Abstract available

    January 2019
  304. COSSU D, Yokoyama K, Sakanishi T, Momotani E, et al
    Adjuvant and antigenic properties of Mycobacterium avium subsp. paratuberculosis on experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2019 Jan 23. pii: S0165-5728(18)30552.
    PubMed     Abstract available

  305. JAYASIMHAN A, Ellis DP, Ziegler AI, Slattery RM, et al
    Pancreatic ductal cell antigens are important in the development of invasive insulitis in Non-Obese Diabetic mice.
    J Neuroimmunol. 2019 Jan 18. pii: S0165-5728(18)30263.
    PubMed     Abstract available

  306. MAUSNER-FAINBERG K, Penn M, Golan M, Benhamou M, et al
    Reduced levels of Coco in sera of multiple sclerosis patients: A potential role in neuro-regeneration failure.
    J Neuroimmunol. 2019 Jan 17. pii: S0165-5728(18)30476.
    PubMed     Abstract available

  307. DOLATI S, Babaloo Z, Ayromlou H, Ahmadi M, et al
    Nanocurcumin improves regulatory T-cell frequency and function in patients with multiple sclerosis.
    J Neuroimmunol. 2019 Jan 17. pii: S0165-5728(18)30466.
    PubMed     Abstract available

  308. KOHLER S, Keil T, Alexander T, Thiel A, et al
    Altered naive CD4(+) T cell homeostasis in myasthenia gravis and thymoma patients.
    J Neuroimmunol. 2019 Jan 11. pii: S0165-5728(18)30380.
    PubMed     Abstract available

    December 2018
  309. EMAMI ALEAGHA MS, Siroos B, Allameh A, Shakiba S, et al
    Calcitriol, but not FGF23, increases in CSF and serum of MS patients.
    J Neuroimmunol. 2018;328:89-93.
    PubMed     Abstract available

  310. DEMIR S, Pitarokoili K, Linker R, Gold R, et al
    Immune cell derived BDNF does not mediate neuroprotection of the murine anti-CD52 antibody in a chronic autoimmune mouse model.
    J Neuroimmunol. 2018;328:78-85.
    PubMed     Abstract available

  311. ARAMIDEH KHOUY R, Karampoor S, Keyvani H, Bokharaei-Salim F, et al
    The frequency of varicella-zoster virus infection in patients with multiple sclerosis receiving fingolimod.
    J Neuroimmunol. 2018;328:94-97.
    PubMed     Abstract available

  312. XIE Y, Li Z, Wang Y, Xue X, et al
    Effects of moderate- versus high- intensity swimming training on inflammatory and CD4(+) T cell subset profiles in experimental autoimmune encephalomyelitis mice.
    J Neuroimmunol. 2018;328:60-67.
    PubMed     Abstract available

  313. MEHTA D, Wani S, Wallace L, Henders AK, et al
    Cumulative influence of parity-related genomic changes in multiple sclerosis.
    J Neuroimmunol. 2018;328:38-49.
    PubMed     Abstract available

  314. YOUSEFI F, Lavi Arab F, Saeidi K, Amiri H, et al
    Various strategies to improve efficacy of stem cell transplantation in multiple sclerosis: Focus on mesenchymal stem cells and neuroprotection.
    J Neuroimmunol. 2018;328:20-34.
    PubMed     Abstract available

    November 2018
  315. LEE EJ, Lim YM, Kim SY, Lee J, et al
    The clinical and prognostic value of antinuclear antibodies in NMO-IgG seropositive neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2018;328:1-4.
    PubMed     Abstract available

  316. MASOUMI F, Ghorbani S, Talebi F, Branton WG, et al
    Malat1 long noncoding RNA regulates inflammation and leukocyte differentiation in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2018;328:50-59.
    PubMed     Abstract available

  317. MONTEIRO A, Cruto C, Rosado P, Rosado L, et al
    Interferon-beta treated-multiple sclerosis patients exhibit a decreased ratio between immature/transitional B cell subset and plasmablasts.
    J Neuroimmunol. 2018;326:49-54.
    PubMed     Abstract available

  318. ANNIBALI V, Umeton R, Palermo A, Severa M, et al
    Analysis of coding and non-coding transcriptome of peripheral B cells reveals an altered interferon response factor (IRF)-1 pathway in multiple sclerosis patients.
    J Neuroimmunol. 2018;324:165-171.
    PubMed     Abstract available

  319. LOTAN I, Hellmann MA, Benninger F, Stiebel-Kalish H, et al
    Recurrent optic neuritis - Different patterns in multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody disease.
    J Neuroimmunol. 2018;324:115-118.
    PubMed     Abstract available

  320. MOORE JR, Hubler SL, Nelson CD, Nashold FE, et al
    1,25-Dihydroxyvitamin D3 increases the methionine cycle, CD4(+) T cell DNA methylation and Helios(+)Foxp3(+) T regulatory cells to reverse autoimmune neurodegenerative disease.
    J Neuroimmunol. 2018;324:100-114.
    PubMed     Abstract available

  321. ROCHA NP, Colpo GD, Bravo-Alegria J, Lincoln JA, et al
    Exploring the relationship between Endothelin-1 and peripheral inflammation in multiple sclerosis.
    J Neuroimmunol. 2018;326:45-48.
    PubMed     Abstract available

  322. WANG SX, Yang CL, Zhang M, Zhang P, et al
    Sulfatides ameliorate experimental autoimmune neuritis by suppressing Th1/Th17 cells.
    J Neuroimmunol. 2018;326:55-61.
    PubMed     Abstract available

  323. BOUXIN M, Schvartz B, Mestrallet S, Debrumetz A, et al
    Rituximab treatment in seronegative autoimmune autonomic neuropathy and autoimmune autonomic ganglionopathy: Case-report and literature review.
    J Neuroimmunol. 2018;326:28-32.
    PubMed     Abstract available

  324. JENSEN PEH, Warnke C, Ingenhoven K, Piccoli L, et al
    Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study.
    J Neuroimmunol. 2018;326:19-27.
    PubMed     Abstract available

    October 2018
  325. RAMIREZ GA, Coletto LA, Bozzolo EP, Citterio L, et al
    The TRPC6 intronic polymorphism, associated with the risk of neurological disorders in systemic lupus erythematous, influences immune cell function.
    J Neuroimmunol. 2018;325:43-53.
    PubMed     Abstract available

  326. CAVAZZANA I, Alberici A, Bonomi E, Ottaviani R, et al
    Antinuclear antibodies in Frontotemporal Dementia: the tip's of autoimmunity iceberg?
    J Neuroimmunol. 2018;325:61-63.
    PubMed     Abstract available

  327. SAFIZADEH B, Hoshyar R, Mehrpour M, Eftekhar M, et al
    The role of expression and activity of 15-Lipoxygenase isoforms and related cytokines in patients with Multiple Sclerosis and healthy controls.
    J Neuroimmunol. 2018;325:32-42.
    PubMed     Abstract available

  328. ROSSETTI I, Zambusi L, Finardi A, Bodini A, et al
    Calcitonin gene-related peptide decreases IL-1beta, IL-6 as well as Ym1, Arg1, CD163 expression in a brain tissue context-dependent manner while ameliorating experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2018;323:94-104.
    PubMed     Abstract available

  329. KVISTAD SS, Myhr KM, Holmoy T, Benth JS, et al
    Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis.
    J Neuroimmunol. 2018;323:73-77.
    PubMed     Abstract available

  330. DUBEY D, Kothapalli N, McKeon A, Flanagan EP, et al
    Predictors of neural-specific autoantibodies and immunotherapy response in patients with cognitive dysfunction.
    J Neuroimmunol. 2018;323:62-72.
    PubMed     Abstract available

  331. DUBEY D, Hussain RZ, Miller-Little WA, Salter A, et al
    PDCB does not promote CNS autoimmunity in the context of genetic susceptibility but worsens its outcome.
    J Neuroimmunol. 2018;323:53-55.
    PubMed     Abstract available

  332. SLAVIN YN, Bo M, Caggiu E, Sechi G, et al
    High levels of antibodies against PtpA and PknG secreted by Mycobacterium avium ssp. paratuberculosis are present in neuromyelitis optica spectrum disorder and multiple sclerosis patients.
    J Neuroimmunol. 2018;323:49-52.
    PubMed     Abstract available

  333. AMORUSO A, Blonda M, D'Arrigo G, Grasso R, et al
    Effect of fingolimod action on the release of monocyte-derived microvesicles in multiple sclerosis patients.
    J Neuroimmunol. 2018;323:43-48.
    PubMed     Abstract available

  334. HOCAOGLU M, Durmus H, Ozkan B, Yentur SP, et al
    Increased costimulatory molecule expression of thymic and peripheral B cells and a sensitivity to IL-21 in myasthenia gravis.
    J Neuroimmunol. 2018;323:36-42.
    PubMed     Abstract available

  335. HAARMANN A, Hahnel L, Schuhmann MK, Buttmann M, et al
    Age-adjusted CSF beta2-microglobulin and lactate are increased and ACE is decreased in patients with multiple sclerosis, but only lactate correlates with clinical disease duration and severity.
    J Neuroimmunol. 2018;323:19-27.
    PubMed     Abstract available

  336. SHAKERIAN L, Ghorbani S, Talebi F, Noorbakhsh F, et al
    MicroRNA-150 targets PU.1 and regulates macrophage differentiation and function in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2018;323:167-174.
    PubMed     Abstract available

  337. DEBNATH M, Nagappa M, Subbanna M, Sundaravadivel P, et al
    Th17 pathway signatures in a large Indian cohort of Guillain Barre syndrome.
    J Neuroimmunol. 2018;323:125-130.
    PubMed     Abstract available

  338. BLUM S, Ji Y, Pennisi D, Li Z, et al
    Genome-wide association study in Guillain-Barre syndrome.
    J Neuroimmunol. 2018;323:109-114.
    PubMed     Abstract available

  339. MOHAMMADZADEH A, Rad IA, Ahmadi-Salmasi B
    CTLA-4, PD-1 and TIM-3 expression predominantly downregulated in MS patients.
    J Neuroimmunol. 2018;323:105-108.
    PubMed     Abstract available

  340. KOSTIC M, Zivkovic N, Cvetanovic A, Stojanovic I, et al
    Granulocyte-macrophage colony-stimulating factor as a mediator of autoimmunity in multiple sclerosis.
    J Neuroimmunol. 2018;323:1-9.
    PubMed     Abstract available

  341. AQEL SI, Granitto MC, Nuro-Gyina PK, Pei W, et al
    Distinct roles for Blimp-1 in autoreactive CD4 T cells during priming and effector phase of autoimmune encephalomyelitis.
    J Neuroimmunol. 2018;325:20-28.
    PubMed     Abstract available

  342. ALROUJI M, Manouchehrinia A, Gran B, Constantinescu CS, et al
    Effects of cigarette smoke on immunity, neuroinflammation and multiple sclerosis.
    J Neuroimmunol. 2018 Oct 9. pii: S0165-5728(18)30130.
    PubMed     Abstract available

  343. SABRE L, Guptill JT, Russo M, Juel VC, et al
    Circulating microRNA plasma profile in MuSK+ myasthenia gravis.
    J Neuroimmunol. 2018 Oct 6. pii: S0165-5728(18)30383.
    PubMed     Abstract available

  344. TAVAKOLPOUR V, Shokri G, Naser Moghadasi A, Mozafari Nahavandi P, et al
    Increased expression of mir-301a in PBMCs of patients with relapsing-remitting multiple sclerosis is associated with reduced NKRF and PIAS3 expression levels and disease activity.
    J Neuroimmunol. 2018 Oct 4. pii: S0165-5728(18)30173.
    PubMed     Abstract available

  345. SUGIMOTO K, Hiwasa T, Shibuya K, Hirano S, et al
    Novel autoantibodies against the proteasome subunit PSMA7 in amyotrophic lateral sclerosis.
    J Neuroimmunol. 2018;325:54-60.
    PubMed     Abstract available

    September 2018
  346. IWASA K, Yoshikawa H, Furukawa Y, Yamada M, et al
    Programmed cell death ligand 1 expression is upregulated in the skeletal muscle of patients with myasthenia gravis.
    J Neuroimmunol. 2018 Sep 27. pii: S0165-5728(18)30353.
    PubMed     Abstract available

  347. CASTOLDI V, Marenna S, Santangelo R, d'Isa R, et al
    Optic nerve involvement in experimental autoimmune encephalomyelitis to homologous spinal cord homogenate immunization in the dark agouti rat.
    J Neuroimmunol. 2018;325:1-9.
    PubMed     Abstract available

  348. JAFARZADEH A, Nemati M
    Therapeutic potentials of ginger for treatment of Multiple sclerosis: A review with emphasis on its immunomodulatory, anti-inflammatory and anti-oxidative properties.
    J Neuroimmunol. 2018;324:54-75.
    PubMed     Abstract available

  349. MCWILLIAM O, Sellebjerg F, Marquart HV, von Essen MR, et al
    B cells from patients with multiple sclerosis have a pathogenic phenotype and increased LTalpha and TGFbeta1 response.
    J Neuroimmunol. 2018 Sep 7. pii: S0165-5728(18)30276.
    PubMed     Abstract available

    August 2018
  350. SALAPA HE, Johnson C, Hutchinson C, Popescu BF, et al
    Dysfunctional RNA binding proteins and stress granules in multiple sclerosis.
    J Neuroimmunol. 2018 Aug 29. pii: S0165-5728(18)30377.
    PubMed     Abstract available

  351. FENOGLIO C, Oldoni E, Serpente M, De Riz MA, et al
    LncRNAs expression profile in peripheral blood mononuclear cells from multiple sclerosis patients.
    J Neuroimmunol. 2018 Aug 27. pii: S0165-5728(18)30259.
    PubMed     Abstract available

  352. HOU H, Cao R, Quan M, Sun Y, et al
    Rapamycin and fingolimod modulate Treg/Th17 cells in experimental autoimmune encephalomyelitis by regulating the Akt-mTOR and MAPK/ERK pathways.
    J Neuroimmunol. 2018;324:26-34.
    PubMed     Abstract available

  353. MORIGUCHI K, Miyamoto K, Fukumoto Y, Kusunoki S, et al
    4-Aminopyridine ameliorates relapsing remitting experimental autoimmune encephalomyelitis in SJL/J mice.
    J Neuroimmunol. 2018;323:131-135.
    PubMed     Abstract available

  354. CHEDRAWE MAJ, Holman SP, Lamport AC, Akay T, et al
    Pioglitazone is superior to quetiapine, clozapine and tamoxifen at alleviating experimental autoimmune encephalomyelitis in mice.
    J Neuroimmunol. 2018;321:72-82.
    PubMed     Abstract available

  355. FEKI S, Gargouri S, Mejdoub S, Dammak M, et al
    The intrathecal polyspecific antiviral immune response (MRZ reaction): A potential cerebrospinal fluid marker for multiple sclerosis diagnosis.
    J Neuroimmunol. 2018;321:66-71.
    PubMed     Abstract available

  356. FAGONE P, Mazzon E, Chikovani T, Saraceno A, et al
    Decitabine induces regulatory T cells, inhibits the production of IFN-gamma and IL-17 and exerts preventive and therapeutic efficacy in rodent experimental autoimmune neuritis.
    J Neuroimmunol. 2018;321:41-48.
    PubMed     Abstract available

  357. LAI W, Kinoshita M, Peng A, Li W, et al
    Does pregnancy affect women with multiple sclerosis? A prospective study in Western China.
    J Neuroimmunol. 2018;321:24-28.
    PubMed     Abstract available

  358. MOHAJER B, Abbasi N, Pishgar F, Abdolalizadeh A, et al
    HLA-DRB1 polymorphism and susceptibility to multiple sclerosis in the Middle East North Africa region: A systematic review and meta-analysis.
    J Neuroimmunol. 2018;321:117-124.
    PubMed     Abstract available

    July 2018
  359. MIYAKE S, Yamamura T
    Gut environmental factors and multiple sclerosis.
    J Neuroimmunol. 2018 Jul 27. pii: S0165-5728(17)30414.
    PubMed     Abstract available

  360. NAKAMURA R, Makino T, Hanada T, Terakawa M, et al
    Heterogeneity of auto-antibodies against nAChR in myasthenic serum and their pathogenic roles in experimental autoimmune myasthenia gravis.
    J Neuroimmunol. 2018;320:64-75.
    PubMed     Abstract available

  361. KARAMPOOR S, Zahednasab H, Etemadifar M, Keyvani H, et al
    The levels of soluble forms of CD21 and CD83 in multiple sclerosis.
    J Neuroimmunol. 2018;320:11-14.
    PubMed     Abstract available

    June 2018
  362. HAASE S, Wilck N, Kleinewietfeld M, Muller DN, et al
    Sodium chloride triggers Th17 mediated autoimmunity.
    J Neuroimmunol. 2018 Jun 30. pii: S0165-5728(17)30512.
    PubMed     Abstract available

  363. SABERI R, Sharif M, Sarvi S, Aghayan SA, et al
    Is Toxoplasma gondii playing a positive role in multiple sclerosis risk? A systematic review and meta-analysis.
    J Neuroimmunol. 2018 Jun 22. pii: S0165-5728(17)30579.
    PubMed     Abstract available

  364. SERAFINI B, Zandee S, Rosicarelli B, Scorsi E, et al
    Epstein-Barr virus-associated immune reconstitution inflammatory syndrome as possible cause of fulminant multiple sclerosis relapse after natalizumab interruption.
    J Neuroimmunol. 2018;319:9-12.

  365. SERIZAWA K, Tomizawa-Shinohara H, Magi M, Yogo K, et al
    Anti-IL-6 receptor antibody improves pain symptoms in mice with experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2018;319:71-79.
    PubMed     Abstract available

  366. TIJERO B, Del Pino R, Perez-Concha T, Acera MA, et al
    Seronegative and seropositive autoimmune autonomic ganglionopathy (AAG): Same clinical picture, same response to immunotherapy.
    J Neuroimmunol. 2018;319:68-70.
    PubMed     Abstract available

  367. YOSHIKURA N, Kimura A, Fukata M, Fukata Y, et al
    Long-term clinical follow-up of a patient with non-paraneoplastic cerebellar ataxia associated with anti-mGluR1 autoantibodies.
    J Neuroimmunol. 2018;319:63-67.
    PubMed     Abstract available

  368. HIRATSUKA D, Furube E, Taguchi K, Tanaka M, et al
    Remyelination in the medulla oblongata of adult mouse brain during experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2018;319:41-54.
    PubMed     Abstract available

  369. AKAISHI T, Takahashi T, Nakashima I
    Peripheral blood monocyte count at onset may affect the prognosis in multiple sclerosis.
    J Neuroimmunol. 2018;319:37-40.
    PubMed     Abstract available

  370. FAGONE P, Mazzon E, Cavalli E, Bramanti A, et al
    Contribution of the macrophage migration inhibitory factor superfamily of cytokines in the pathogenesis of preclinical and human multiple sclerosis: In silico and in vivo evidences.
    J Neuroimmunol. 2018 Jun 15. pii: S0165-5728(18)30141.
    PubMed     Abstract available

    May 2018
  371. DUPREE JL, Feinstein DL
    Influence of diet on axonal damage in the EAE mouse model of multiple sclerosis.
    J Neuroimmunol. 2018 May 20. pii: S0165-5728(18)30104.
    PubMed     Abstract available

  372. BREUER J, Loser K, Mykicki N, Wiendl H, et al
    Does the environment influence multiple sclerosis pathogenesis via UVB light and/or induction of vitamin D?
    J Neuroimmunol. 2018 May 18. pii: S0165-5728(17)30478.
    PubMed     Abstract available

  373. CHU F, Shi M, Zheng C, Shen D, et al
    The roles of macrophages and microglia in multiple sclerosis and experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2018;318:1-7.
    PubMed     Abstract available

  374. SABRE L, Maddison P, Sadalage G, Ambrose PA, et al
    Circulating microRNA miR-21-5p, miR-150-5p and miR-30e-5p correlate with clinical status in late onset myasthenia gravis.
    J Neuroimmunol. 2018 May 8. pii: S0165-5728(18)30122.
    PubMed     Abstract available

    April 2018
  375. DUBEY D, Hinson SR, Jolliffe EA, Zekeridou A, et al
    Autoimmune GFAP astrocytopathy: Prospective evaluation of 90 patients in 1year.
    J Neuroimmunol. 2018 Apr 27. pii: S0165-5728(18)30160.
    PubMed     Abstract available

  376. CASTANEDA-MORENO VA, De la Cruz-Mosso U, Torres-Carrillo N, Macias-Islas MA, et al
    MIF functional polymorphisms (-794 CATT5-8 and -173 G>C) are associated with MIF serum levels, severity and progression in male multiple sclerosis from western Mexican population.
    J Neuroimmunol. 2018 Apr 10. pii: S0165-5728(17)30593.
    PubMed     Abstract available

  377. YAN J, Winterford CM, Catts VS, Pat BK, et al
    Increased constitutive activation of NF-kappaB p65 (RelA) in peripheral blood cells of patients with progressive multiple sclerosis.
    J Neuroimmunol. 2018 Apr 6. pii: S0165-5728(17)30536.
    PubMed     Abstract available

  378. LI J, Qiu D, Chen Z, Du W, et al
    miR-548k regulates CXCL13 expression in myasthenia gravis patients with thymic hyperplasia and in Jurkat cells.
    J Neuroimmunol. 2018 Apr 4. pii: S0165-5728(18)30166.
    PubMed     Abstract available

    March 2018
  379. ZAGORITI Z, Lagoumintzis G, Perroni G, Papathanasiou G, et al
    Evidence for association of STAT4 and IL12RB2 variants with Myasthenia gravis susceptibility: What is the effect on gene expression in thymus?
    J Neuroimmunol. 2018 Mar 17. pii: S0165-5728(17)30559.
    PubMed     Abstract available

  380. ALLENDER E, Deol H, Schram S, Maheras KJ, et al
    Neuregulin1 modulation of experimental autoimmune encephalomyelitis (EAE).
    J Neuroimmunol. 2018 Mar 10. pii: S0165-5728(17)30466.
    PubMed     Abstract available

  381. PAUNOVIC V, Petrovic IV, Milenkovic M, Janjetovic K, et al
    Autophagy-independent increase of ATG5 expression in T cells of multiple sclerosis patients.
    J Neuroimmunol. 2018 Mar 5. pii: S0165-5728(17)30538.
    PubMed     Abstract available

  382. SMITH PA, Schmid C, Zurbruegg S, Jivkov M, et al
    Fingolimod inhibits brain atrophy and promotes brain-derived neurotrophic factor in an animal model of multiple sclerosis.
    J Neuroimmunol. 2018 Mar 3. pii: S0165-5728(17)30519.
    PubMed     Abstract available

  383. ASHTARI F, Esmaeil N, Mansourian M, Poursafa P, et al
    An 8-year study of people with multiple sclerosis in Isfahan, Iran: Association between environmental air pollutants and severity of disease.
    J Neuroimmunol. 2018 Mar 2. pii: S0165-5728(18)30019.
    PubMed     Abstract available

    February 2018
  384. MONTEIRO A, Cruto C, Rosado P, Martinho A, et al
    Characterization of circulating gamma-delta T cells in relapsing vs remission multiple sclerosis.
    J Neuroimmunol. 2018 Feb 24. pii: S0165-5728(17)30533.
    PubMed     Abstract available

  385. BARBOUR M, Wood R, Hridi SU, Wilson C, et al
    The therapeutic effect of anti-CD52 treatment in murine experimental autoimmune encephalomyelitis is associated with altered IL-33 and ST2 expression levels.
    J Neuroimmunol. 2018 Feb 24. pii: S0165-5728(17)30457.
    PubMed     Abstract available

  386. ROZMILOWSKA IM, Adamczyk-Sowa MH
    What is the role of interleukin 33 and ST2 receptor in myasthenia gravis?
    J Neuroimmunol. 2018;315:50-57.

  387. KUHN I, Rogosch T, Schindler TI, Tackenberg B, et al
    Serum titers of autoantibodies against alpha-synuclein and tau in child- and adulthood.
    J Neuroimmunol. 2018;315:33-39.
    PubMed     Abstract available

  388. GEORGE JD, Kim E, Spain R, Bourdette D, et al
    Effects of lipoic acid on migration of human B cells and monocyte-enriched peripheral blood mononuclear cells in relapsing remitting multiple sclerosis.
    J Neuroimmunol. 2018;315:24-27.
    PubMed     Abstract available

  389. IP PP, Chung CY, Chang CC, Lee YF, et al
    Differentiation of remitting neuromyelitis optica spectrum disorders from multiple sclerosis by integrating parameters from serum proteins and lymphocyte subsets.
    J Neuroimmunol. 2018 Feb 8. pii: S0165-5728(17)30498.
    PubMed     Abstract available

    January 2018
  390. LIU C, Liu H, Jin H, Yue X, et al
    Cholinergic imbalance in lumbar spinal cord of a rat model of multiple sclerosis.
    J Neuroimmunol. 2018 Jan 31. pii: S0165-5728(17)30560.
    PubMed     Abstract available

  391. HOR JY, Lim TT, Cheng MC, Chia YK, et al
    Thymoma-associated myasthenia gravis and LGI1-encephalitis, with nephrotic syndrome post-thymectomy.
    J Neuroimmunol. 2018 Jan 30. pii: S0165-5728(17)30491.
    PubMed     Abstract available

  392. RAHMAN MI, Jahan I, Khalid MM, Jahan I, et al
    CD1A and CD1E gene polymorphisms are not associated with susceptibility to Guillain-Barre syndrome in the Bangladeshi population.
    J Neuroimmunol. 2018;314:8-12.
    PubMed     Abstract available

  393. MEYER SAUTEUR PM, Huizinga R, Tio-Gillen AP, Drenthen J, et al
    Intrathecal antibody responses to GalC in Guillain-Barre syndrome triggered by Mycoplasma pneumoniae.
    J Neuroimmunol. 2018;314:13-16.
    PubMed     Abstract available

  394. LOSHAJ-SHALA A, Colzani M, Brezovska K, Poceva Panovska A, et al
    Immunoproteomic identification of antigenic candidate Campylobacter jejuni and human peripheral nerve proteins involved in Guillain-Barre syndrome.
    J Neuroimmunol. 2018 Jan 9. pii: S0165-5728(17)30422.
    PubMed     Abstract available

  395. VOGRIG A, Pauletto G, Belgrado E, Pegolo E, et al
    Effect of thymectomy on refractory autoimmune status epilepticus.
    J Neuroimmunol. 2018 Jan 9. pii: S0165-5728(17)30485.
    PubMed     Abstract available

  396. LV J, Li L, Li W, Ji K, et al
    Role of the chemokine receptors CXCR3, CXCR4 and CCR7 in the intramuscular recruitment of plasmacytoid dendritic cells in dermatomyositis.
    J Neuroimmunol. 2018 Jan 9. pii: S0165-5728(18)30015.
    PubMed     Abstract available

  397. BAULINA N, Kulakova O, Kiselev I, Osmak G, et al
    Immune-related miRNA expression patterns in peripheral blood mononuclear cells differ in multiple sclerosis relapse and remission.
    J Neuroimmunol. 2018 Jan 5. pii: S0165-5728(17)30447.
    PubMed     Abstract available

  398. MASUDA H, Mori M, Umehara K, Furihata T, et al
    Soluble CD40 ligand disrupts the blood-brain barrier and exacerbates inflammation in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2018 Jan 3. pii: S0165-5728(17)30562.
    PubMed     Abstract available

  399. OZKUL C, Guclu-Gunduz A, Irkec C, Fidan I, et al
    Effect of combined exercise training on serum brain-derived neurotrophic factor, suppressors of cytokine signaling 1 and 3 in patients with multiple sclerosis.
    J Neuroimmunol. 2018 Jan 3. pii: S0165-5728(17)30484.
    PubMed     Abstract available

    December 2017
  400. DETRICK B, Gangaputra S, Palsgrove DN, Heaney CD, et al
    Elevated serum levels of IL-6 and CXCL9 in autoimmune retinopathy (AIR) patients.
    J Neuroimmunol. 2017 Dec 29. pii: S0165-5728(17)30269.
    PubMed     Abstract available

  401. IMITOLA J, Rasouli J, Watanabe F, Mahajan K, et al
    Elevated expression of granulocyte-macrophage colony-stimulating factor receptor in multiple sclerosis lesions.
    J Neuroimmunol. 2017 Dec 22. pii: S0165-5728(17)30304.
    PubMed     Abstract available

  402. ROLLA S, De Mercanti SF, Bardina V, Horakova D, et al
    Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses.
    J Neuroimmunol. 2017;313:89-91.
    PubMed     Abstract available

  403. BHAT R, Mahapatra S, Axtell RC, Steinman L, et al
    Amelioration of ongoing experimental autoimmune encephalomyelitis with fluoxetine.
    J Neuroimmunol. 2017;313:77-81.
    PubMed     Abstract available

  404. TAYLOR JM
    Tissue resident macrophages are sufficient for demyelination during peripheral nerve myelin induced experimental autoimmune neuritis?
    J Neuroimmunol. 2017;313:69-76.
    PubMed     Abstract available

  405. LI R, Sun X, Shu Y, Wang Y, et al
    Serum CCL20 and its association with SIRT1 activity in multiple sclerosis patients.
    J Neuroimmunol. 2017;313:56-60.
    PubMed     Abstract available

  406. GILLI F, Royce DB, DiSano KD, Pachner AR, et al
    Pegylated interferon beta in the treatment of the Theiler's murine encephalomyelitis virus mouse model of multiple sclerosis.
    J Neuroimmunol. 2017;313:34-40.
    PubMed     Abstract available

  407. LIU J, Lian Z, Chen H, Shi Z, et al
    Associations between tumor necrosis factor-alpha gene polymorphisms and the risk of Guillain-Barre syndrome and its subtypes: A systematic review and meta-analysis.
    J Neuroimmunol. 2017;313:25-33.
    PubMed     Abstract available

  408. AKAISHI T, Kaneko K, Himori N, Takeshita T, et al
    Subclinical retinal atrophy in the unaffected fellow eyes of multiple sclerosis and neuromyelitis optica.
    J Neuroimmunol. 2017;313:10-15.
    PubMed     Abstract available

  409. GLENN JD, Xue P, Whartenby KA
    Gemcitabine directly inhibits effector CD4 T cell activation and prevents experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2017 Dec 8. pii: S0165-5728(17)30303.
    PubMed     Abstract available

  410. BANSI J, Koliamitra C, Bloch W, Joisten N, et al
    Persons with secondary progressive and relapsing remitting multiple sclerosis reveal different responses of tryptophan metabolism to acute endurance exercise and training.
    J Neuroimmunol. 2017 Dec 6. pii: S0165-5728(17)30420.
    PubMed     Abstract available

    November 2017
  411. KIM MJ, Lim JY, Park SA, Park SI, et al
    Effective combination of methylprednisolone and interferon beta-secreting mesenchymal stem cells in a model of multiple sclerosis.
    J Neuroimmunol. 2017 Nov 29. pii: S0165-5728(17)30134.
    PubMed     Abstract available

  412. MONTELEONE F, Nicoletti CG, Stampanoni Bassi M, Iezzi E, et al
    Nerve growth factor is elevated in the CSF of patients with multiple sclerosis and central neuropathic pain.
    J Neuroimmunol. 2017 Nov 20. pii: S0165-5728(17)30179.
    PubMed     Abstract available

  413. YOSHIKURA N, Kimura A, Hayashi Y, Inuzuka T, et al
    Corrigendum to Anti-C1q autoantibodies in patients with neuromyelitis optica spectrum disorders" [J. Neuroimmunol. 310. (2017) 150-157].
    J Neuroimmunol. 2017;312:66.

  414. WANG Y, Zhang W, Yin J, Lu Q, et al
    Anti-N-methyl-d-aspartate receptor encephalitis in children of Central South China: Clinical features, treatment, influencing factors, and outcomes.
    J Neuroimmunol. 2017;312:59-65.
    PubMed     Abstract available

  415. HESSELMARK E, Bejerot S
    Biomarkers for diagnosis of Pediatric Acute Neuropsychiatric Syndrome (PANS) - Sensitivity and specificity of the Cunningham Panel.
    J Neuroimmunol. 2017;312:31-37.
    PubMed     Abstract available

  416. SVEINSSON O, Granqvist M, Forslin Y, Blennow K, et al
    Successful combined targeting of B- and plasma cells in treatment refractory anti-NMDAR encephalitis.
    J Neuroimmunol. 2017;312:15-18.
    PubMed     Abstract available

  417. ROLF L, Muris AH, Theunissen R, Hupperts R, et al
    Vitamin D3 supplementation and the IL-2/IL-2R pathway in multiple sclerosis: Attenuation of progressive disturbances?
    J Neuroimmunol. 2017 Nov 10. pii: S0165-5728(17)30208.
    PubMed     Abstract available

  418. MAZDEH M, Moradi N, Khoshroo E, Shayesteh Z, et al
    Down-regulation of TYK2, CBLB and LMP7 genes expression in relapsing-remitting multiple sclerosis patients treated with interferon-beta.
    J Neuroimmunol. 2017 Nov 8. pii: S0165-5728(17)30405.
    PubMed     Abstract available

    October 2017
  419. LIU W, Zhu M, Yu Z, Yin D, et al
    Therapeutic effects of diosgenin in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2017 Oct 31. pii: S0165-5728(17)30191.
    PubMed     Abstract available

  420. PALTERER B, Brugnolo F, Sieni E, Barilaro A, et al
    Neuromyelitis optica, atypical hemophagocytic lymphohistiocytosis and heterozygous perforin A91V mutation.
    J Neuroimmunol. 2017;311:10-13.
    PubMed     Abstract available

  421. LEI HW, Wang JY, Dang QJ, Yang F, et al
    Neuropsychiatric involvement in lupus is associated with the Nogo-a/NgR1 pathway.
    J Neuroimmunol. 2017;311:22-28.
    PubMed     Abstract available

  422. HUANG ZL, Pandya D, Banta DK, Ansari MS, et al
    Cyclophilin inhibitor NIM811 ameliorates experimental allergic encephalomyelitis.
    J Neuroimmunol. 2017;311:40-48.
    PubMed     Abstract available

    September 2017
  423. FERNANDEZ HURST N, Zanetti SR, Baez NS, Bibolini MJ, et al
    Diazepam treatment reduces inflammatory cells and mediators in the central nervous system of rats with experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2017 Sep 30. pii: S0165-5728(17)30297.
    PubMed     Abstract available

  424. MERKER M, Eichler S, Herrmann AM, Wiendl H, et al
    Rivaroxaban ameliorates disease course in an animal model of multiple sclerosis.
    J Neuroimmunol. 2017 Sep 21. pii: S1521-6616(17)30639.
    PubMed     Abstract available

  425. BADIHIAN S, Manouchehri N, Badihian N
    More evidence is needed to show any role of cytomegalovisrus and varicella zoster virus in pathogenesis of multiple sclerosis.
    J Neuroimmunol. 2017 Sep 18. pii: S0165-5728(17)30401.

  426. VILLANI S, Zanotta N, Ambrogi F, Comar M, et al
    Multiplex array analysis of circulating cytokines and chemokines in natalizumab-treated patients with multiple sclerosis.
    J Neuroimmunol. 2017;310:91-96.
    PubMed     Abstract available

  427. CHANGYALEKET B, Deliu Z, Chignalia AZ, Feinstein DL, et al
    Heparanase: Potential roles in multiple sclerosis.
    J Neuroimmunol. 2017;310:72-81.
    PubMed     Abstract available

  428. JAHAN I, Ahammad RU, Farzana KS, Khalid MM, et al
    Tumor necrosis factor-alpha -863C/A polymorphism is associated with Guillain-Barre syndrome in Bangladesh.
    J Neuroimmunol. 2017;310:46-50.
    PubMed     Abstract available

  429. NIELSEN BR, Ratzer R, Bornsen L, von Essen MR, et al
    Characterization of naive, memory and effector T cells in progressive multiple sclerosis.
    J Neuroimmunol. 2017;310:17-25.
    PubMed     Abstract available

  430. HAITAO R, Huiqin L, Tao Q, Xunzhe Y, et al
    Autoimmune encephalitis associated with vitiligo?
    J Neuroimmunol. 2017;310:14-16.
    PubMed     Abstract available

  431. DELGADO-GARCIA G, Corona-Vazquez T
    IgG4-related disease and IgG4-mediated neurological autoimmune disorders: One and the same?
    J Neuroimmunol. 2017;310:129-130.

  432. PENN M, Mausner-Fainberg K, Golan M, Karni A, et al
    High serum levels of BMP-2 correlate with BMP-4 and BMP-5 levels and induce reduced neuronal phenotype in patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2017;310:120-128.
    PubMed     Abstract available

  433. BENEDEK G, Zhang J, Nguyen H, Kent G, et al
    Estrogen protection against EAE modulates the microbiota and mucosal-associated regulatory cells.
    J Neuroimmunol. 2017;310:51-59.
    PubMed     Abstract available

  434. ZHU DS, Yu L, Li M, Han L, et al
    High serum creatinine is associated with reduction of vision impaired in patients with NMOSD.
    J Neuroimmunol. 2017;310:32-37.
    PubMed     Abstract available

  435. WANG J, Yang C, Zhao Q, Zhu Z, et al
    Microglia activation induced by serum of SLE patients.
    J Neuroimmunol. 2017;310:135-142.
    PubMed     Abstract available

    Antibodies to the Epstein-Barr virus proteins BFRF3 and BRRF2 cross-react with human proteins.
    J Neuroimmunol. 2017;310:131-134.
    PubMed     Abstract available

  437. ALVARENGA MP, Fernandez O, Leyva L, Campanella L, et al
    The HLA DRB1*03:01 allele is associated with NMO regardless of the NMO-IgG status in Brazilian patients from Rio de Janeiro.
    J Neuroimmunol. 2017;310:1-7.
    PubMed     Abstract available

  438. VERCELLINO M, Trebini C, Capello E, Mancardi GL, et al
    Inflammatory responses in Multiple Sclerosis normal-appearing white matter and in non-immune mediated neurological conditions with wallerian axonal degeneration: A comparative study.
    J Neuroimmunol. 2017 Sep 8. pii: S0165-5728(17)30131.
    PubMed     Abstract available

  439. LAZARIDIS K, Dalianoudis I, Baltatzidi V, Tzartos SJ, et al
    Specific removal of autoantibodies by extracorporeal immunoadsorption ameliorates experimental autoimmune myasthenia gravis.
    J Neuroimmunol. 2017 Sep 6. pii: S0165-5728(17)30332.
    PubMed     Abstract available

    August 2017
  440. YESHOKUMAR AK, Gordon-Lipkin E, Arenivas A, Cohen J, et al
    Neurobehavioral outcomes in autoimmune encephalitis.
    J Neuroimmunol. 2017 Aug 31. pii: S0165-5728(17)30274.
    PubMed     Abstract available

  441. ALVAREZ BRAVO G, Yusta Izquierdo A, Carvalho Monteiro G, Sanchez I, et al
    Cerebellopathy secondary to anti-peroxidase antibody-mediated toxicity. A special case of Hashimoto encephalopathy.
    J Neuroimmunol. 2017 Aug 19. pii: S0165-5728(17)30265.
    PubMed     Abstract available

  442. LIU RT, Zhang P, Yang CL, Pang Y, et al
    ONX-0914, a selective inhibitor of immunoproteasome, ameliorates experimental autoimmune myasthenia gravis by modulating humoral response.
    J Neuroimmunol. 2017 Aug 18. pii: S0165-5728(17)30182.
    PubMed     Abstract available

  443. LISAK RP, Nedelkoska L, Benjamins JA, Schalk D, et al
    B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons in vitro.
    J Neuroimmunol. 2017;309:88-99.
    PubMed     Abstract available

  444. WALLWITZ U, Brock S, Schunck A, Wildemann B, et al
    From dizziness to severe ataxia and dysarthria: New cases of anti-Ca/ARHGAP26 autoantibody-associated cerebellar ataxia suggest a broad clinical spectrum.
    J Neuroimmunol. 2017;309:77-81.
    PubMed     Abstract available

  445. PITAROKOILI K, Kohle F, Motte J, Fatoba O, et al
    Anti-inflammatory and immunomodulatory potential of human immunoglobulin applied intrathecally in Lewis rat experimental autoimmune neuritis.
    J Neuroimmunol. 2017;309:58-67.
    PubMed     Abstract available

  446. DEMARSHALL C, Goldwaser EL, Sarkar A, Godsey GA, et al
    Autoantibodies as diagnostic biomarkers for the detection and subtyping of multiple sclerosis.
    J Neuroimmunol. 2017;309:51-57.
    PubMed     Abstract available

  447. CAROTENUTO A, Scalia G, Ausiello F, Moccia M, et al
    CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients.
    J Neuroimmunol. 2017;309:47-50.
    PubMed     Abstract available

  448. MATHEY EK, Garg N, Park SB, Nguyen T, et al
    Autoantibody responses to nodal and paranodal antigens in chronic inflammatory neuropathies.
    J Neuroimmunol. 2017;309:41-46.
    PubMed     Abstract available

  449. KARAMPOOR S, Zahednasab H, Ramagopalan S, Mehrpour M, et al
    Cytomegalovirus and varicella zoster virus seropositivity of Iranian patients with multiple sclerosis: A population-based study.
    J Neuroimmunol. 2017;309:4-6.
    PubMed     Abstract available

  450. BETTENCOURT A, Boleixa D, Guimaraes AL, Leal B, et al
    The vitamin D receptor gene FokI polymorphism and Multiple Sclerosis in a Northern Portuguese population.
    J Neuroimmunol. 2017;309:34-37.
    PubMed     Abstract available

  451. PIERI M, Storto M, Pignalosa S, Zenobi R, et al
    KFLC Index utility in multiple sclerosis diagnosis: Further confirmation.
    J Neuroimmunol. 2017;309:31-33.
    PubMed     Abstract available

  452. LI X, Lin J, Pan S, Weng Y, et al
    Suspected bacterial meningomyelitis: The first presenting clinical feature of neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2017;309:68-71.
    PubMed     Abstract available

  453. KON T, Ueno T, Suzuki C, Nunomura J, et al
    Aquaporin-4 antibody positive neuromyelitis optica spectrum disorder associated with esophageal cancer.
    J Neuroimmunol. 2017;309:38-40.
    PubMed     Abstract available

  454. LIU J, Shi Z, Lian Z, Chen H, et al
    Association of CD58 gene polymorphisms with NMO spectrum disorders in a Han Chinese population.
    J Neuroimmunol. 2017;309:23-30.
    PubMed     Abstract available

  455. HENDRICKX DAE, van Eden CG, Schuurman KG, Hamann J, et al
    Staining of HLA-DR, Iba1 and CD68 in human microglia reveals partially overlapping expression depending on cellular morphology and pathology.
    J Neuroimmunol. 2017;309:12-22.
    PubMed     Abstract available

  456. SUCHDEV K, Razmjou S, Venkatachalam P, Khan OA, et al
    Late onset neuromyelitis optica mimicking an acute stroke in an elderly patient.
    J Neuroimmunol. 2017;309:1-3.
    PubMed     Abstract available

  457. AHMAD SF, Ansari MA, Nadeem A, Bakheet SA, et al
    Adenosine A2A receptor signaling affects IL-21/IL-22 cytokines and GATA3/T-bet transcription factor expression in CD4+ T cells from a BTBR T+ Itpr3tf/J mouse model of autism.
    J Neuroimmunol. 2017 Aug 9. pii: S0165-5728(17)30253.
    PubMed     Abstract available

  458. WILDNER P, Selmaj KW
    Multiple sclerosis: Skin-induced antigen-specific immune tolerance.
    J Neuroimmunol. 2017 Aug 2. pii: S0165-5728(17)30263.
    PubMed     Abstract available

    July 2017
  459. YOSHIKURA N, Kimura A, Hayashi Y, Inuzuka T, et al
    Anti-C1q autoantibodies in patients with neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2017 Jul 19. pii: S0165-5728(17)30144.
    PubMed     Abstract available

    June 2017
  460. LIU G, Zhang F, Hu Y, Jiang Y, et al
    Multiple sclerosis risk pathways differ in Caucasian and Chinese populations.
    J Neuroimmunol. 2017;307:63-68.
    PubMed     Abstract available

  461. ASMAIL A, Kesler A, Drory VE, Kolb H, et al
    Effect of ethnic origin and gender on the clinical manifestations of myasthenia gravis among the Jewish population in Israel.
    J Neuroimmunol. 2017;307:47-52.
    PubMed     Abstract available

  462. FERNANDO KTM, James M
    Early predictors of rapidly evolving multiple sclerosis: A case report.
    J Neuroimmunol. 2017;307:42-46.
    PubMed     Abstract available

  463. ZAHOOR I, Haq E
    Multiple sclerosis in India: Iceberg or volcano.
    J Neuroimmunol. 2017;307:27-30.
    PubMed     Abstract available

  464. SAUER EL, Trifilieff E, Greer JM
    Predicting the effects of potentially therapeutic modified peptides on polyclonal T cell populations in a mouse model of multiple sclerosis.
    J Neuroimmunol. 2017;307:18-26.
    PubMed     Abstract available

  465. SERAFINI B, Scorsi E, Rosicarelli B, Rigau V, et al
    Massive intracerebral Epstein-Barr virus reactivation in lethal multiple sclerosis relapse after natalizumab withdrawal.
    J Neuroimmunol. 2017;307:14-17.
    PubMed     Abstract available

  466. KINOSHITA M, Daifu M, Tanaka K, Tanaka M, et al
    Prognostic value of oligoclonal IgG bands in Japanese clinically isolated syndrome converting to clinically definite multiple sclerosis.
    J Neuroimmunol. 2017;307:1-6.
    PubMed     Abstract available

  467. BARROS PO, Dias ASO, Kasahara TM, Ornelas AMM, et al
    Expansion of IL-6+ Th17-like cells expressing TLRs correlates with microbial translocation and neurological disabilities in NMOSD patients.
    J Neuroimmunol. 2017;307:82-90.
    PubMed     Abstract available

    May 2017
  468. JING S, Song Y, Song J, Pang S, et al
    Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis.
    J Neuroimmunol. 2017 May 30. pii: S0165-5728(17)30074.
    PubMed     Abstract available

  469. AKAISHI T, Nakashima I, Mugikura S, Aoki M, et al
    Whole brain and grey matter volume of Japanese patients with multiple sclerosis.
    J Neuroimmunol. 2017;306:68-75.
    PubMed     Abstract available

  470. SISAY S, Lopez-Lozano L, Mickunas M, Quiroga-Fernandez A, et al
    Untreated relapsing remitting multiple sclerosis patients show antibody production against latent Epstein Barr Virus (EBV) antigens mainly in the periphery and innate immune IL-8 responses preferentially in the CNS.
    J Neuroimmunol. 2017;306:40-45.
    PubMed     Abstract available

  471. CONSTANTINESCU R, Krysl D, Andren K, Asztely F, et al
    Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying malignancies.
    J Neuroimmunol. 2017;306:25-30.
    PubMed     Abstract available

  472. BERMUDEZ-MORALES VH, Fierros G, Lopez RL, Martinez-Nava G, et al
    Vitamin D receptor gene polymorphisms are associated with multiple sclerosis in Mexican adults.
    J Neuroimmunol. 2017;306:20-24.
    PubMed     Abstract available

  473. RAMAKRISHNAN V, Akram Husain RS, Ahmed SS
    Genetic predisposition of IL-10 promoter polymorphisms with risk of multiple sclerosis: A meta-analysis.
    J Neuroimmunol. 2017;306:11-18.
    PubMed     Abstract available

  474. SELMAJ I, Mycko MP, Raine CS, Selmaj KW, et al
    The role of exosomes in CNS inflammation and their involvement in multiple sclerosis.
    J Neuroimmunol. 2017;306:1-10.
    PubMed     Abstract available

    April 2017
  475. AGLIARDI C, Guerini FR, Zanzottera M, Bolognesi E, et al
    Vitamin D-binding protein gene polymorphisms are not associated with MS risk in an Italian cohort.
    J Neuroimmunol. 2017;305:92-95.
    PubMed     Abstract available

  476. DENG B, Liu XN, Li X, Zhang X, et al
    Raised cerebrospinal fluid BAFF and APRIL levels in anti-N-methyl-d-aspartate receptor encephalitis: Correlation with clinical outcome.
    J Neuroimmunol. 2017;305:84-91.
    PubMed     Abstract available

  477. BENEDEK G, Zhang J, Nguyen H, Kent G, et al
    Novel feedback loop between M2 macrophages/microglia and regulatory B cells in estrogen-protected EAE mice.
    J Neuroimmunol. 2017;305:59-67.
    PubMed     Abstract available

  478. ZHOU L, Huang Y, Li H, Fan J, et al
    MOG-antibody associated demyelinating disease of the CNS: A clinical and pathological study in Chinese Han patients.
    J Neuroimmunol. 2017;305:19-28.
    PubMed     Abstract available

  479. SCOTT TF
    Understanding the impact of relapses in the overall course of MS; refinement of the 2 stage natural history model.
    J Neuroimmunol. 2017;305:162-166.
    PubMed     Abstract available

  480. PAWLAK-ADAMSKA E, Nowak O, Karabon L, Pokryszko-Dragan A, et al
    PD-1 gene polymorphic variation is linked with first symptom of disease and severity of relapsing-remitting form of MS.
    J Neuroimmunol. 2017;305:115-127.
    PubMed     Abstract available

  481. KIMURA A, Takemura M, Saito K, Serrero G, et al
    Increased cerebrospinal fluid progranulin correlates with interleukin-6 in the acute phase of neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2017;305:175-181.
    PubMed     Abstract available

    February 2017
  482. PANT AB, Wang Y, Mielcarz DW, Kasper EJ, et al
    Alteration of CD39+Foxp3+ CD4 T cell and cytokine levels in EAE/MS following anti-CD52 treatment.
    J Neuroimmunol. 2017;303:22-30.
    PubMed     Abstract available

  483. LAZARIDIS K, Baltatzidi V, Trakas N, Koutroumpi E, et al
    Characterization of a reproducible rat EAMG model induced with various human acetylcholine receptor domains.
    J Neuroimmunol. 2017;303:13-21.
    PubMed     Abstract available

  484. WARNECKE A, Musunuri S, N'diaye M, Sandalova T, et al
    Nitration of MOG diminishes its encephalitogenicity depending on MHC haplotype.
    J Neuroimmunol. 2017;303:1-12.
    PubMed     Abstract available

    January 2017
  485. ZHANGBAO J, Zhou L, Li X, Cai T, et al
    The clinical characteristics of AQP4 antibody positive NMO/SD in a large cohort of Chinese Han patients.
    J Neuroimmunol. 2017;302:49-55.
    PubMed     Abstract available

    December 2016
  486. VOLPE G, Bernstock JD, Peruzzotti-Jametti L, Pluchino S, et al
    Modulation of host immune responses following non-hematopoietic stem cell transplantation: Translational implications in progressive multiple sclerosis.
    J Neuroimmunol. 2016 Dec 15. pii: S0165-5728(16)30312.
    PubMed     Abstract available

    November 2016
  487. COVACU R, Brundin L
    Endogenous spinal cord stem cells in multiple sclerosis and its animal model.
    J Neuroimmunol. 2016 Nov 15. pii: S0165-5728(16)30403.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.